



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 219/10, 493/04, A61L 2/18, C07F 9/64, 9/6561, C07D 405/12 // (C07D 493/04, 311:00, 307:00)	A1	(11) International Publication Number: WO 98/30545 (43) International Publication Date: 16 July 1998 (16.07.98)
(21) International Application Number: PCT/US98/00532 (22) International Filing Date: 6 January 1998 (06.01.98) (30) Priority Data: 08/779,885 6 January 1997 (06.01.97) US 08/779,830 7 January 1997 (07.01.97) US 60/043,696 15 April 1997 (15.04.97) US (71) Applicant (for all designated States except US): CERUS CORPORATION [US/US]; Suite 300, 2525 Stanwell Drive, Concord, CA 94520 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): COOK, David [US/US]; 3399 Freeman Road, Walnut Creek, CA 94595 (US). MERRITT, John [US/US]; 1001 Millbrook Court, Walnut Creek, CA 94598 (US). NERJO, Aileen [US/US]; 2361 Carpenter Court, Fremont, CA 94539 (US). RAPOPORT, Henry [US/US]; 6 Hillcrest Court, Fremont, CA 94705 (US). STASSINOPOULOS, Adonis [US/US]; 7685 Shady Creek Road, Dublin, CA 94568 (US). WOLLOWITZ, Susan [US/US]; 764 Beale Court, Walnut Creek, CA 94598 (US). MATEJOVIC, Jon [CA/CA]; -		(74) Agents: JOHNSTON, Madeline, I. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>With amended claims.</i>
(54) Title: FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION (57) Abstract Compounds and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in biological materials such as red blood cell preparations and plasma. The compounds and methods may be used to treat materials intended for <i>in vitro</i> or <i>in vivo</i> use, such as clinical testing or transfusion. The compounds are designed to specifically bind to and react with nucleic acid, and then to degrade to form breakdown products. The degradation reaction is preferably slower than the reaction with nucleic acid.		

09/872,466 CERUS-5100
 Adonis Stassinopoulos
 Contact: Linda Aston
 (925) 288-6107

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Licchtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

10 **FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION**

CROSS-REFERENCE TO RELATED APPLICATIONS

 This application claims the benefit of U.S. Provisional Application Serial
No. 60/043,696, filed April 15, 1997, the disclosure of which is incorporated
15 herein by reference.

 This application also is a continuation-in-part of U.S. Patent Application
Serial No. 08/779,885, filed January 6, 1997; and is a continuation-in-part of U.S.
Patent Application Serial No. 08/779,830, filed January 6, 1997, the disclosures of
20 which are incorporated herein by reference.

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER
 FEDERALLY SPONSORED RESEARCH

 This invention was made with United States government support under
25 Grant 1-RO1-HL41221 from the NHLBI. The United States Government has
certain rights in this invention.

TECHNICAL FIELD

30 This invention relates to compounds which are useful for inactivating
pathogens in a material, such as a blood product, and to methods of use of the
compounds.

BACKGROUND ART

5 The transmission of disease by blood products and other biological materials remains a serious health problem. While significant advances in blood donor screening and blood testing have occurred, viruses such as hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV) may escape detection in blood products during testing due to low levels of virus or viral antibodies. In addition to the viral hazard, there are currently no licensed tests to
10 screen for the presence of bacteria or protozoans in blood intended for use in transfusions. The risk also exists that a hitherto unknown pathogen may become prevalent in the blood supply and present a threat of disease transmission, as in fact occurred before the recognition of the risk of HIV transmission via blood transfusions.

15 Exposure of laboratory workers to blood or other body fluids also presents a health hazard. Twelve thousand health-care workers whose jobs involve exposure to blood are infected with hepatitis B virus each year, according to estimates from the Centers for Disease Control ("Guidelines for Prevention of Transmission of Human Immunodeficiency Virus and Hepatitis B Virus to
20 Health-Care and Public-Safety Workers," Morbidity and Mortality Weekly Report, vol. 38, no. S-6, June 1989).

25 Several methods have been proposed to complement donor screening and blood testing to decrease the incidence of disease due to transfusions. The introduction of chemical agents into blood or blood plasma has been suggested to inactivate pathogens prior to clinical use of the blood product. Nitrogen mustard, $\text{CH}_3\text{-N}(\text{CH}_2\text{CH}_2\text{Cl})_2$, was added to blood components in an investigation of potential virucidal agents. However, substantial hemolysis occurred at the concentrations necessary to inactivate one of the viruses studied, rendering nitrogen mustard unsuitable for use in blood. LoGrippo *et al.*, Proceedings of the

Sixth Congress of the International Society of Blood Transfusion, Bibliotheca Haematologica (Hollander, ed.), 1958, pp. 225-230.

A "solvent/detergent" (S/D) method for inactivating viruses was described in Horowitz *et al.*, *Blood* 79:826 (1992) and in Horowitz *et al.*, *Transfusion* 25:516 (1985). This method utilized 1% tri(n-butyl)phosphate and 1% Triton X-100 at 30 °C for 4 hours to inactivate viruses in fresh frozen plasma. Piquet *et al.*, *Vox Sang.* 63:251 (1992), used 1% tri(n-butyl)phosphate and 1% Octoxynol-9 to inactivate viruses in fresh frozen plasma. Another method for inactivating viruses in blood involves the addition of phenol or formaldehyde to the blood. U.S. Patent No. 4,833,165. However, both the solvent/detergent method and the phenol/formaldehyde method require removal of the chemical additives prior to clinical use of the blood product.

Inactivation of pathogens in blood products using photoactivated agents has also been described; see, e.g., Wagner *et al.*, *Transfusion*, 34:521 (1994). However, due to the absorption of light by hemoglobin in several regions in the ultraviolet and visible spectrum, phototreatment is limited in its application to materials containing red blood cells. There is also some indication that phototreatment of red blood cells alters the cells in some manner; see Wagner *et al.*, *Transfusion* 33:30 (1993).

There is thus a need for compositions and methods for treating blood, blood-derived products, and other biological materials, which will inactivate pathogens present in the products or materials without rendering the products or materials unsuitable for their intended use. Compositions which do not need to be removed from the biological material prior to its use would be particularly useful, as equipment and supplies needed to remove the compositions would be obviated and the costs of handling the biological material would be reduced. This places an additional requirement on the composition, however, in that if the composition remains in the biological material, it must not pose a hazard when the biological material is used for its intended purpose. For example, a highly toxic compound which inactivates pathogens in a blood sample would preclude the use of that

blood for transfusion purposes (although the blood sample may still be suitable for laboratory analysis).

It is one intention of this invention to provide compositions and methods of use of the compositions for inactivating pathogens in biological materials, without rendering the materials unsuitable for their intended purpose. Examples of how this may be accomplished include, but are not limited to, using the compounds in an *ex vivo* or *in vitro* treatment of the biological materials and then removing the compounds prior to the use of the material; by using a composition which, even though it remains in the material, does not render the material unsuitable for its intended use; or by using a composition which, after inactivating pathogens in the material, will break down to products, where the breakdown products can remain in the material without rendering the material unsuitable for its intended use.

DISCLOSURE OF THE INVENTION

Accordingly, it is an object of this invention to provide compounds for inactivating pathogens in a material, where such compounds comprise a nucleic acid binding moiety; an effector moiety, capable of forming a covalent bond with nucleic acid; and a frangible linker covalently linking the nucleic acid moiety and the effector moiety; wherein the frangible linker degrades so as to no longer covalently link the nucleic acid binding moiety and the effector moiety, under conditions which do not render the material unsuitable for its intended purpose.

It is an additional object of this invention to provide such compounds for inactivating pathogens in a material, wherein the nucleic acid binding moiety is selected from the group consisting of acridine, acridine derivatives, psoralen, isopsoralen and psoralen derivatives.

It is an additional object of this invention to provide such compounds for inactivating pathogens in a material, wherein the frangible linker comprises a functional unit selected from the group consisting of forward esters, reverse esters,


forward amides, reverse amides, forward thioesters, reverse thioesters, forward and reverse thionoesters, forward and reverse dithioic acids, sulfates, forward and reverse sulfonates, phosphates, and forward and reverse phosphonate groups, as defined herein.

5 It is an additional object of this invention to provide such compounds for inactivating pathogens in a material, wherein the effector group comprises a functional unit which is an alkylating agent.

It is an additional object of this invention to provide such compounds for inactivating pathogens in a material, wherein the effector group comprises a
10 functional unit selected from the group consisting of mustard groups, mustard group equivalents, epoxides, aldehydes, and formaldehyde synthons.

It is an additional object of this invention to provide compounds of the formula:

15



wherein at least one of R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 and R_9 is -V-W-X-E as defined below, and the remainder of R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 and R_9 are
20 independently selected from the group consisting of -H, $-R_{10}$, $-O-R_{10}$, $-NO_2$, $-NH_2$, $-NH-R_{10}$, $-N(R_{10})_2$, -F, -Cl, -Br, -I, $-C(=O)-R_{10}$, $-C(=O)-O-R_{10}$, and $-O-C(=O)-R_{10}$,

where $-R_{10}$ is independently H, $-C_{1-8}$ alkyl, $-C_{1-8}$ heteroalkyl, -aryl, -heteroaryl, $-C_{1-3}$ alkyl-aryl, $-C_{1-3}$ heteroalkyl-aryl, $-C_{1-3}$ alkyl-heteroaryl, $-C_{1-3}$ heteroalkyl-heteroaryl, -aryl- $-C_{1-3}$ alkyl, -aryl- $-C_{1-3}$ heteroalkyl,
25 -heteroaryl- $-C_{1-3}$ alkyl, -heteroaryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ alkyl,


-C₁₋₃heteroalkyl-aryl-C₁₋₃ alkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃alkyl-aryl-C₁₋₃ heteroalkyl, -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃heteroalkyl-aryl-C₁₋₃ heteroalkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ heteroalkyl, or -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ heteroalkyl;

5 V is independently -R₁₁-, -NH-R₁₁- or -N(CH₃)-R₁₁-, where -R₁₁- is independently -C₁₋₈alkyl-, -C₁₋₈heteroalkyl-, -aryl-, -heteroaryl-, -C₁₋₃alkyl-aryl-, -C₁₋₃heteroalkyl-aryl-, -C₁₋₃alkyl-heteroaryl-, -C₁₋₃heteroalkyl-heteroaryl-, -aryl-C₁₋₃alkyl-, -aryl-C₁₋₃heteroalkyl-, -heteroaryl-C₁₋₃alkyl-, -heteroaryl-C₁₋₃heteroalkyl-, -C₁₋₃alkyl-aryl-C₁₋₃ alkyl-, -C₁₋₃heteroalkyl-aryl-C₁₋₃ alkyl-, -C₁₋₃alkyl-heteroaryl-C₁₋₃ alkyl-, -C₁₋₃alkyl-aryl-C₁₋₃ heteroalkyl-, -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ alkyl-, -C₁₋₃heteroalkyl-aryl-C₁₋₃ heteroalkyl-, -C₁₋₃alkyl-heteroaryl-C₁₋₃ heteroalkyl-, or -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ heteroalkyl-;

15 W is independently -C(=O)-O-, -O-C(=O)-, -C(=S)-O-, -O-C(=S)-, -C(=S)-S-, -S-C(=S)-, -C(=O)-S-, -S-C(=O)-, -O-S(=O)₂-O-, -S(=O)₂-O-, -O-S(=O)₂-, -C(=O)-NR₁₀-, -NR₁₀-C(=O)-, -O-P(=O)(-OR₁₀)-O-, -P(=O)(-OR₁₀)-O-, -O-P(=O)(-OR₁₀)-;

X is independently -R₁₁-; and

20 E is independently selected from the group consisting of -N(R₁₂)₂, -N(R₁₂)(R₁₃), -S-R₁₂, and




where -R₁₂ is -CH₂CH₂-G, where each G is independently -Cl, -Br, -I, -O-S(=O)₂-CH₃, -O-S(=O)₂-CH₂-C₆H₅, or -O-S(=O)₂-C₆H₄-CH₃;

25 and where R₁₃ is independently -C₁₋₈ alkyl, -C₁₋₈ heteroalkyl, -aryl, -heteroaryl, -C₁₋₃alkyl-aryl, -C₁₋₃heteroalkyl-aryl, -C₁₋₃alkyl-heteroaryl, -C₁₋₃heteroalkyl-heteroaryl, -aryl-C₁₋₃alkyl, -aryl-C₁₋₃heteroalkyl, -heteroaryl-C₁₋₃alkyl, -heteroaryl-C₁₋₃heteroalkyl, -C₁₋₃alkyl-aryl-C₁₋₃ alkyl,

-C₁₋₃heteroalkyl-aryl-C₁₋₃ alkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃alkyl-aryl-C₁₋₃ heteroalkyl, -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃heteroalkyl-aryl-C₁₋₃ heteroalkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ heteroalkyl, or
-C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ heteroalkyl;

5 and all salts and stereoisomers (including enantiomers and diastereomers) thereof.

It is another object of this invention to provide compounds of the formula:



10 where R₁, R₂, R₃, R₄, R₅, R₆, R₇, and R₈ are independently selected from the group consisting of -H, -R₁₀, -O-R₁₀, -NO₂, -NH₂, -NH-R₁₀, -N(R₁₀)₂, -F, -Cl, -Br, -I, -C(=O)-R₁₀, -C(=O)-O-R₁₀, and -O-C(=O)-R₁₀,

15 where -R₁₀ is independently H, -C₁₋₈ alkyl, -C₁₋₈ heteroalkyl, -aryl, -heteroaryl, -C₁₋₃alkyl-aryl, -C₁₋₃heteroalkyl-aryl, -C₁₋₃alkyl-heteroaryl, -C₁₋₃heteroalkyl-heteroaryl, -aryl-C₁₋₃alkyl, -aryl-C₁₋₃heteroalkyl, -heteroaryl-C₁₋₃alkyl, -heteroaryl-C₁₋₃heteroalkyl, -C₁₋₃alkyl-aryl-C₁₋₃ alkyl, -C₁₋₃heteroalkyl-aryl-C₁₋₃ alkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃alkyl-aryl-C₁₋₃ heteroalkyl, -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃heteroalkyl-aryl-C₁₋₃ heteroalkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ heteroalkyl, or
20 -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ heteroalkyl;

R₂₀ is -H or -CH₃; and

R₂₁ is -R₁₁-W-X-E,


25 where -R₁₁- is independently -C₁₋₈alkyl-, -C₁₋₈heteroalkyl-, -aryl-, -heteroaryl-, -C₁₋₃alkyl-aryl-, -C₁₋₃heteroalkyl-aryl-, -C₁₋₃alkyl-heteroaryl-,

-C₁₋₃heteroalkyl-heteroaryl-, -aryl-C₁₋₃alkyl-, -aryl-C₁₋₃heteroalkyl-,
 -heteroaryl-C₁₋₃alkyl-, -heteroaryl-C₁₋₃heteroalkyl-, -C₁₋₃alkyl-aryl-C₁₋₃ alkyl-,
 -C₁₋₃heteroalkyl-aryl-C₁₋₃ alkyl-, -C₁₋₃alkyl-heteroaryl-C₁₋₃ alkyl-,
 -C₁₋₃alkyl-aryl-C₁₋₃ heteroalkyl-, -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ alkyl-,
 5 -C₁₋₃heteroalkyl-aryl-C₁₋₃ heteroalkyl-, -C₁₋₃alkyl-heteroaryl-C₁₋₃ heteroalkyl-, or
 -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ heteroalkyl-;

W is independently -C(=O)-O-, -O-C(=O)-, -C(=S)-O-, -O-C(=S)-,
 -C(=S)-S-, -S-C(=S)-, -C(=O)-S-, -S-C(=O)-, -O-S(=O)₂-O-, -S(=O)₂-O-,
 -O-S(=O)₂-, -C(=O)-NR₁₀-, -NR₁₀-C(=O)-, -O-P(=O)(-OR₁₀)-O-,
 10 -P(=O)(-OR₁₀)-O-, -O-P(=O)(-OR₁₀)-;

X is independently -R₁₁-; and

E is independently selected from the group consisting of -N(R₁₂)₂,
 -N(R₁₂)(R₁₃), -S-R₁₂,
 and




15 where -R₁₂ is -CH₂CH₂-G, where each G is independently -Cl, -Br, -I,
 -O-S(=O)₂-CH₃, -O-S(=O)₂-CH₂-C₆H₅, or -O-S(=O)₂-C₆H₄-CH₃;

and where R₁₃ is independently -C₁₋₈ alkyl, -C₁₋₈ heteroalkyl, -aryl,
 -heteroaryl, -C₁₋₃alkyl-aryl, -C₁₋₃heteroalkyl-aryl, -C₁₋₃alkyl-heteroaryl,
 20 -C₁₋₃heteroalkyl-heteroaryl, -aryl-C₁₋₃alkyl, -aryl-C₁₋₃heteroalkyl,
 -heteroaryl-C₁₋₃alkyl, -heteroaryl-C₁₋₃heteroalkyl, -C₁₋₃alkyl-aryl-C₁₋₃ alkyl,
 -C₁₋₃heteroalkyl-aryl-C₁₋₃ alkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃alkyl-aryl-C₁₋₃
 heteroalkyl, -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃heteroalkyl-aryl-C₁₋₃
 heteroalkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ heteroalkyl, or
 25 -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ heteroalkyl;

and all salts and stereoisomers (including enantiomers and diastereomers)
 thereof.

It is another object of this invention to provide compounds of the formula:



5 wherein at least one of R_{44} , R_{55} , R_3 , R_4 , R_5 , and R_8 is -V-W-X-E, and the remainder of R_{44} , R_{55} , R_3 , R_4 , R_5 , and R_8 are independently selected from the group consisting of -H, $-R_{10}$, $-O-R_{10}$, $-NO_2$, $-NH_2$, $-NH-R_{10}$, $-N(R_{10})_2$, -F, -Cl, -Br, -I, $-C(=O)-R_{10}$, $-C(=O)-O-R_{10}$, and $-O-C(=O)-R_{10}$,

10 where $-R_{10}$ is independently H, $-C_{1-8}$ alkyl, $-C_{1-8}$ heteroalkyl, -aryl, -heteroaryl, $-C_{1-3}$ alkyl-aryl, $-C_{1-3}$ heteroalkyl-aryl, $-C_{1-3}$ alkyl-heteroaryl, $-C_{1-3}$ heteroalkyl-heteroaryl, -aryl- $-C_{1-3}$ alkyl, -aryl- $-C_{1-3}$ heteroalkyl, -heteroaryl- $-C_{1-3}$ alkyl, -heteroaryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ heteroalkyl, or $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ heteroalkyl;

15 V is independently $-R_{11}$ -, $-NH-R_{11}$ - or $-N(CH_3)-R_{11}$ -, where $-R_{11}$ - is independently $-C_{1-8}$ alkyl-, $-C_{1-8}$ heteroalkyl-, -aryl-, -heteroaryl-, $-C_{1-3}$ alkyl-aryl-, $-C_{1-3}$ heteroalkyl-aryl-, $-C_{1-3}$ alkyl-heteroaryl-, $-C_{1-3}$ heteroalkyl-heteroaryl-, $-C_{1-3}$ alkyl-aryl-, $-C_{1-3}$ heteroalkyl-aryl-, -heteroaryl- $-C_{1-3}$ alkyl-, -heteroaryl- $-C_{1-3}$ heteroalkyl-, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ heteroalkyl-, $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ heteroalkyl-, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ heteroalkyl-, or $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ heteroalkyl-;

20


25

W is independently -C(=O)-O-, -O-C(=O)-, -C(=S)-O-, -O-C(=S)-, -C(=S)-S-, -S-C(=S)-, -C(=O)-S-, -S-C(=O)-, -O-S(=O)₂-O-, -S(=O)₂-O-, -O-S(=O)₂-, -C(=O)-NR₁₀-, -NR₁₀-C(=O)-, -O-P(=O)(-OR₁₀)-O-, -P(=O)(-OR₁₀)-O-, -O-P(=O)(-OR₁₀)-;

5 X is independently -R₁₁-; and

E is independently selected from the group consisting of -N(R₁₂)₂, -N(R₁₂)(R₁₃), -S-R₁₂,

and



10 where -R₁₂ is -CH₂CH₂-G, where each G is independently -Cl, -Br, -I, -O-S(=O)₂-CH₃, -O-S(=O)₂-CH₂-C₆H₅, or -O-S(=O)₂-C₆H₄-CH₃;

and where R₁₃ is independently -C₁₋₈ alkyl, -C₁₋₈ heteroalkyl, -aryl, -heteroaryl, -C₁₋₃alkyl-aryl, -C₁₋₃heteroalkyl-aryl, -C₁₋₃alkyl-heteroaryl, -C₁₋₃heteroalkyl-heteroaryl, -aryl-C₁₋₃alkyl, -aryl-C₁₋₃heteroalkyl, -heteroaryl-C₁₋₃alkyl, -heteroaryl-C₁₋₃heteroalkyl, -C₁₋₃alkyl-aryl-C₁₋₃ alkyl, -C₁₋₃heteroalkyl-aryl-C₁₋₃ alkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃alkyl-aryl-C₁₋₃ heteroalkyl, -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃heteroalkyl-aryl-C₁₋₃ heteroalkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ heteroalkyl, or -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ heteroalkyl;

20 and all salts and stereoisomers (including enantiomers and diastereomers) thereof.

It is yet another object of this invention to provide the compounds β-alanine, N-(2-carbomethoxyacridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester; 4-aminobutyric acid N-[(2-carbomethoxyacridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester; 5-aminovaleric acid N-[(2-carbomethoxyacridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester; β-alanine, N-(2-carbomethoxyacridin-

9-yl), 3-[bis(2-chloroethyl)amino]propyl ester; β -alanine, [N,N-bis(2-chloroethyl)], 3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl ester; β -alanine, [N,N-bis(2-chloroethyl)], 2-[(6-chloro-2-methoxyacridin-9-yl)amino]ethyl ester; [N,N-bis(2-chloroethyl)]-2-aminoethyl 4,5',8-trimethyl-4'-psoralenacetate; and β -alanine, N-(acridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester; and all salts thereof.

Provided are methods for inactivating pathogens in a material, such as a biological material, the methods comprising adding one or more compounds of the invention to the material; and incubating the material. The compound may be added to the material to form a final solution having a concentration of the compound (or total concentration of all compounds, if more than one is used), for example, of between 1 and 500 μ M. Biological materials which may be treated include blood, blood products, plasma, platelet preparations, red blood cells, packed red blood cells, serum, cerebrospinal fluid, saliva, urine, sweat, feces, semen, milk, tissue samples, and homogenized tissue samples, derived from human or other mammalian or vertebrate sources.

BEST MODE FOR CARRYING OUT THE INVENTION

This invention provides for compounds useful for inactivating pathogens found in materials, particularly for inactivating pathogens found in biological materials such as blood or other body fluids. This invention also provides for methods of use of such compounds for inactivating pathogens in materials. The invention also provides for inactivating pathogens found in or on materials for biological use. The compounds may be used *in vitro* and *ex vivo*. The biological materials or materials for biological use may be intended for use *in vitro*, *in vivo*, or *ex vivo*.

The compounds are designed to inactivate pathogens by reacting with nucleic acid. In aqueous solution, at appropriate pH values, the compounds have a period of activity during which they can bind to and react with nucleic acid. After this period, the compounds break down to products which are no longer able to bind to nor react with nucleic acid.

The chemical organization of the compounds can be broadly described as an anchor, covalently bonded to a frangible linker, which is covalently bonded to an effector. "Anchor" is defined as a moiety which binds non-covalently to a nucleic acid biopolymer (DNA or RNA). "Effector" is defined as a moiety which reacts with nucleic acid by a mechanism which forms a covalent bond with the nucleic acid. "Frangible linker" is defined as a moiety which serves to covalently link the anchor and effector, and which will degrade under certain conditions so that the anchor and effector are no longer linked covalently. The anchor-frangible linker-effector arrangement enables the compounds to bind specifically to nucleic acid (due to the anchor's binding ability). This brings the effector into proximity for reaction with the nucleic acid.

The compounds are useful for inactivating pathogens found in materials, particularly biological materials such as blood and other body fluids. Intracellular and extracellular and or other pathogen materials may be inactivated. For example, when a compound of the invention is combined with a pathogen-containing red blood cell composition at physiological pH, the effector portion of the compound reacts with pathogen nucleic acid. Effector moieties which do not react with nucleic acid are gradually hydrolyzed by the solvent. Hydrolysis of the frangible linker occurs concurrently with the effector-nucleic acid reaction and effector hydrolysis. It is desirable that the frangible linker break down at a rate slow enough to permit inactivation of pathogens in the material; that is, the rate of breakdown of the frangible linker is slower than the rate at which the compound reacts with nucleic acid. After a sufficient amount of time has passed, the compound has broken down into the anchor (which may also bear fragments of the frangible linker) and the effector-nucleic acid breakdown products (where

fragments of the frangible linker may also remain attached to the effector), or into the anchor (which may also bear fragments of the frangible linker) and the hydrolyzed effector breakdown products (where fragments of the frangible linker may also remain attached to the effector). Additional fragments of the frangible linker may also be generated upon degradation of the compound which do not remain bonded to either the anchor or the effector. The exact embodiment of the compound of the invention determines whether the anchor breakdown product or the effector breakdown product bears fragments of the frangible linker, or whether additional fragments of the frangible linker are generated which do not remain bonded to either the anchor or the effector breakdown products.

A preferred embodiment of the invention comprises compounds which, upon cleavage of the frangible linker, result in breakdown products of low mutagenicity. Mutagenicity of the compounds, after hydrolysis of the effector, is due primarily to the anchor moiety, as the anchor interacts with nucleic acid and may have the potential to interfere with nucleic acid replication, even if the effector moiety has been hydrolyzed. Preferably, after cleavage of the frangible linker, the anchor fragment has substantially reduced mutagenicity.

Definitions

"Pathogen" is defined as any nucleic acid containing agent capable of causing disease in a human, other mammals, or vertebrates. Examples include microorganisms such as unicellular or multicellular microorganisms. Examples of pathogens are bacteria, viruses, protozoa, fungi, yeasts, molds, and mycoplasmas which cause disease in humans, other mammals, or vertebrates. The genetic material of the pathogen may be DNA or RNA, and the genetic material may be present as single-stranded or double-stranded nucleic acid. The nucleic acid of the pathogen may be in solution, intracellular, extracellular, or bound to cells. Table I lists examples of viruses, and is not intended to limit the invention in any manner.

Table I

Family:	Virus:
Adeno	Adenovirus 2
	Canine hepatitis
Arena	Pichinde
	Lassa
Bunya	Turlock
	California encephalitis
Herpes	Herpes simplex 1
	Herpes simplex 2
	Cytomegalovirus
	Pseudorabies
Orothomyxo	Influenza
Papova	SV-40
Paramyxo	Measles
	Mumps
	Parainfluenza 2 and 3
Picorna	Poliovirus 1 and 2
	Coxsackie A-9
	Echo 11
Pox	Vaccinia
	Fowl Pox
Reo	
	Blue tongue
	Colorado tick fever
Retro	HIV
	Avian sarcoma
	Murine sarcoma
	Murine leukemia
Rhabdo	Vesicular stomatitis virus
Toga	Western equine encephalitis
	Dengue 2
	Dengue 4
	St. Louis encephalitis
Hepadna	hepatitis B
Bacteriophage	Lambda
	T2
(Rickettsia)	R. akari (rickettsialpox)

“*In vivo*” use of a material or compound is defined as introduction of the material or compound into a living human, mammal, or vertebrate.

“*In vitro*” use of a material or compound is defined as a use of the material or compound outside a living human, mammal, or vertebrate, where neither the material nor compound is intended for reintroduction into a living human, mammal, or vertebrate. An example of an *in vitro* use would be the analysis of components of a blood sample using laboratory equipment.

“*Ex vivo*” use of a compound is defined as using a compound for treatment of a biological material outside a living human, mammal, or vertebrate, where that treated biological material is intended for use inside a living human, mammal, or vertebrate. For example, removal of blood from a human, and introduction of a compound into that blood to inactivate pathogens, is defined as an *ex vivo* use of that compound if the blood is intended for reintroduction into that human or another human. Reintroduction of the human blood into that human or another human would be *in vivo* use of the blood, as opposed to the *ex vivo* use of the compound. If the compound is still present in the blood when it is reintroduced into the human, then the compound, in addition to its *ex vivo* use, is also introduced *in vivo*.

“Biological material” is defined as a material originating from a biological organism of any type. Examples of biological materials include, but are not limited to, blood, blood products such as plasma, platelet preparations, red blood cells, packed red blood cells, and serum, cerebrospinal fluid, saliva, urine, feces, semen, sweat, milk, tissue samples, homogenized tissue samples, and any other substance having its origin in a biological organism. Biological materials also include synthetic material incorporating a substance having its origin in a biological organism, such as a vaccine preparation comprised of alum and a pathogen (the pathogen, in this case, being the substance having its origin in a biological organism), a sample prepared for analysis which is a mixture of blood and analytical reagents, cell culture medium, cell cultures, viral cultures, and other cultures derived from a living organism.

“Material for biological use” is defined as any material that will come into contact with, or be introduced into, a living human, mammal, or vertebrate, where

such contact carries a risk of transmitting disease or pathogens. Such materials include, but are not limited to, medical implants such as pacemakers and artificial joints; implants designed for sustained drug release; needles, intravenous lines, and the like; dental tools; dental materials such as tooth crowns; catheters; and any other material which, when in contact with or introduced into a living human, mammal, or vertebrate, entails risk of transmitting disease or pathogens.

“Inactivation of pathogens” is defined as rendering pathogens in a material incapable of reproducing. Inactivation is expressed as the negative logarithm of the fraction of remaining pathogens capable of reproducing. Thus, if a compound at a certain concentration renders 99% of the pathogens in a material incapable of reproduction, 1% or one-one hundredth (0.01) of the pathogens remain capable of reproduction. The negative logarithm of 0.01 is 2, and that concentration of that compound is said to have inactivated the pathogens present by 2 logs.

Alternatively, the compound is said to have 2 logs kill at that concentration.

“Alkyl” as used herein refers to a cyclic, branched, or straight chain chemical group containing carbon and hydrogen, such as methyl, pentyl, and adamantyl. Alkyl groups can either be unsubstituted or substituted with one or more substituents, e.g., halogen, alkoxy, acyloxy, amino, hydroxyl, thiol, carboxy, benzyloxy, phenyl, benzyl, or other functionality. Alkyl groups can be saturated or unsaturated (e.g., containing $-C=C-$ or $-C\equiv C-$ subunits), at one or several positions. Typically, alkyl groups will comprise 1 to 12 carbon atoms, preferably 1 to 10 carbon atoms, and more preferably 1 to 8 carbon atoms, unless otherwise specified.

“Heteroalkyl” as used herein are alkyl chains with one or more N, O, S, or P heteroatoms incorporated into the chain. The heteroatom(s) may bear none, one, or more than one of the substituents described above. “Heteroatoms” also includes oxidized forms of the heteroatoms N, S and P. Examples of heteroalkyl groups include (but are not limited to) methoxy, ethoxy, and other alkyloxy groups; ether-containing groups; amide containing groups such as polypeptide chains; ring systems such as piperidiny, lactam and lactone; and other groups

which incorporate heteroatoms into the carbon chain. Typically, heteroalkyl groups will comprise, in addition to the heteroatom(s), 1 to 12 carbon atoms, preferably 1 to 10 carbon atoms, and more preferably 1 to 8 carbon atoms, unless otherwise specified.

5 “Aryl” or “Ar” refers to an unsaturated aromatic carbocyclic group having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl), which can be optionally unsubstituted or substituted with amino, hydroxyl, C₁₋₈ alkyl, alkoxy, halo, thiol, and other substituents.

10 “Heteroaryl” groups are unsaturated aromatic carbocyclic groups having a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., acridinyl, indolyl or benzothienyl) and having at least one hetero atom, such as N, O, or S, within at least one of the rings. The ring(s) can optionally be unsubstituted or substituted with amino, hydroxyl, alkyl, alkoxy, halo, thiol, acyloxy, carboxy, benzyloxy, phenyl, benzyl, and other substituents.

15

Abbreviations

The following abbreviations are used: QM (quinacrine mustard); Hct (hematocrit); RBC (red blood cell); LB (Luria Broth); cfu (colony forming units); pfu (plaque forming units); DMEM (Delbecco's modified eagles medium); FBS
20 (fetal bovine serum); PRBC (packed red blood cells); rpm (revolutions per minute); TC (tissue culture); NHSP (normal human serum pool); NCS (newborn calf serum); PBS (phosphate buffered saline).

Chemical Structure of the Compounds

25 A wide variety of groups are available for use as the anchors, linkers, and effectors. Examples of anchor groups which can be used in the compound include, but are not limited to, intercalators, minor groove binders, major groove binders, molecules which bind by electrostatic interactions such as polyamines, and molecules which bind by sequence specific interactions. The following is a
30 non-limiting list of possible anchor groups:

acridines (and acridine derivatives, e.g. proflavine, acriflavine, diacridines, acridones, benzacridines, quinacridines), actinomycins, anthracyclines, rhodomycins, daunomycin, thioxanthenones (and thioxanthene derivatives, e.g. miracil D), anthramycin, mitomycins, echinomycin (quinomycin A), triostins, ellipticine (and dimers, trimers and analogs thereof), norphilin A, fluorenes (and derivatives, e.g. flourenones, fluorenodiamines), phenazines, phenanthridines, phenothiazines (e.g., chlorpromazine), phenoxazines, benzothiazoles, xanthenes and thioxanthenes, anthraquinones, anthrapyrazoles, benzothiopyranoindoles, 3,4-benzopyrene, 1-pyrenyloxirane, benzanthracenes, benzodipyrones, quinolines (e.g., chloroquine, quinine, phenylquinoline carboxamides), furocoumarins (e.g., psoralens and isopsoralens), ethidium, propidium, coralyne, and polycyclic aromatic hydrocarbons and their oxirane derivatives;

distamycin, netropsin, other lexitropsins, Hoechst 33258 and other Hoechst dyes, DAPI (4',6-diamidino-2-phenylindole), berenil, and triarylmethane dyes;

aflatoxins;

spermine, spermidine, and other polyamines; and

nucleic acids or analogs which bind by sequence specific interactions such as triple helix formation, D-loop formation, and direct base pairing to single stranded targets. Derivatives of these compounds are also non-limiting examples of anchor groups, where a derivative of a compound includes, but is not limited to, a compound which bears one or more substituent of any type at any location, oxidation or reduction products of the compound, etc.

Examples of linkers which can be used in the invention are, but are not limited to, compounds which include functional groups such as ester (where the carbonyl carbon of the ester is between the anchor and the sp^3 oxygen of the ester; this arrangement is also called "forward ester"), "reverse ester" (where the sp^3 oxygen of the ester is between the anchor and the carbonyl carbon of the ester), thioester (where the carbonyl carbon of the thioester is between the anchor and the sulfur of the thioester, also called "forward thioester"), reverse thioester (where

the sulfur of the thioester is between the anchor and the carbonyl carbon of the thioester, also called "reverse thioester"), forward and reverse thionoester, forward and reverse dithioic acid, sulfate, forward and reverse sulfonates, phosphate, and forward and reverse phosphonate groups. "Thioester" designates the -C(=O)-S- group; "thionoester" designates the -C(=S)-O- group, and "dithioic acid" designates the -C(=S)-S- group. The frangible linker also may include an amide, where the carbonyl carbon of the amide is between the anchor and the nitrogen of the amide (also called a "forward amide"), or where the nitrogen of the amide is between the anchor and the carbonyl carbon of the amide (also called a "reverse amide"). For groups which can be designated as "forward" and "reverse", the forward orientation is that orientation of the functional groups wherein, after hydrolysis of the functional group, the resulting acidic function is covalently linked to the anchor moiety and the resulting alcohol or thiol function is covalently linked to the effector moiety. The reverse orientation is that orientation of the functional groups wherein, after hydrolysis of the functional group, the resulting acidic function is covalently linked to the effector moiety and the resulting alcohol or thiol function is covalently linked to the anchor moiety.


The frangible linker, such as an amide moiety, also may be capable of degrading under conditions of enzymatic degradation, by endogenous enzymes in the biological material being treated, or by enzymes added to the material.

Examples of effectors which can be used in the invention are, but are not limited to, mustard groups, mustard group equivalents, epoxides, aldehydes, formaldehyde synthons, and other alkylating and cross-linking agents. Mustard groups are defined as including mono or bis haloethylamine groups, and mono haloethylsulfide groups. Mustard group equivalents are defined by groups that react by a mechanism similar to the mustards (that is, by forming an aziridinium intermediate, or by having or by forming an aziridine ring, which can react with a nucleophile), such as mono or bis mesylethylamine groups, mono mesylethylsulfide groups, mono or bis tosylethylamine groups, and mono tosylethylsulfide groups. Formaldehyde synthons are defined as any compound

that breaks down to formaldehyde in aqueous solution, including hydroxymethylamines such as hydroxymethylglycine. Examples of formaldehyde synthons are given in U.S. Pat. No. 4,337,269 and in International Patent Application WO 97/02028. While the invention is not limited to any specific mechanism, the effector groups, which are, or are capable of forming an electrophilic group, such as a mustard group, are believed to react with and form a covalent bond to nucleic acid.

Three embodiments of the compounds of this invention are described by the following general formulas I, II, and III.

General formula I is:



(I)

wherein at least one of R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 and R_9 is -V-W-X-E as defined below, and the remainder of R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 and R_9 are independently selected from the group consisting of -H, $-R_{10}$, $-O-R_{10}$, $-NO_2$, $-NH_2$, $-NH-R_{10}$, $-N(R_{10})_2$, -F, -Cl, -Br, -I, $-C(=O)-R_{10}$, $-C(=O)-O-R_{10}$, and $-O-C(=O)-R_{10}$,


where $-R_{10}$ is independently H, $-C_{1-8}$ alkyl, $-C_{1-8}$ heteroalkyl, -aryl, -heteroaryl, $-C_{1-3}$ alkyl-aryl, $-C_{1-3}$ heteroalkyl-aryl, $-C_{1-3}$ alkyl-heteroaryl, $-C_{1-3}$ heteroalkyl-heteroaryl, -aryl- $-C_{1-3}$ alkyl, -aryl- $-C_{1-3}$ heteroalkyl, -heteroaryl- $-C_{1-3}$ alkyl, -heteroaryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ heteroalkyl, or $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ heteroalkyl;

V is independently $-R_{11}$ -, $-NH-R_{11}$ - or $-N(CH_3)-R_{11}$ -, where $-R_{11}$ - is independently $-C_{1-8}alkyl$ -, $-C_{1-8}heteroalkyl$ -, $-aryl$ -, $-heteroaryl$ -, $-C_{1-3}alkyl-aryl$ -, $-C_{1-3}heteroalkyl-aryl$ -, $-C_{1-3}alkyl-heteroaryl$ -, $-C_{1-3}heteroalkyl-heteroaryl$ -, $-aryl-C_{1-3}alkyl$ -, $-aryl-C_{1-3}heteroalkyl$ -, $-heteroaryl-C_{1-3}alkyl$ -, $-heteroaryl-C_{1-3}heteroalkyl$ -, $-C_{1-3}alkyl-aryl-C_{1-3}alkyl$ -, $-C_{1-3}heteroalkyl-aryl-C_{1-3}alkyl$ -, $-C_{1-3}alkyl-heteroaryl-C_{1-3}alkyl$ -, $-C_{1-3}alkyl-aryl-C_{1-3}heteroalkyl$ -, $-C_{1-3}heteroalkyl-heteroaryl-C_{1-3}alkyl$ -, $-C_{1-3}heteroalkyl-aryl-C_{1-3}heteroalkyl$ -, $-C_{1-3}alkyl-heteroaryl-C_{1-3}heteroalkyl$ -, or $-C_{1-3}heteroalkyl-heteroaryl-C_{1-3}heteroalkyl$;

W is independently $-C(=O)-O$ -, $-O-C(=O)$ -, $-C(=S)-O$ -, $-O-C(=S)$ -, $-C(=S)-S$ -, $-S-C(=S)$ -, $-C(=O)-S$ -, $-S-C(=O)$ -, $-O-S(=O)_2-O$ -, $-S(=O)_2-O$ -, $-O-S(=O)_2$ -, $-C(=O)-NR_{10}$ -, $-NR_{10}-C(=O)$ -, $-O-P(=O)(-OR_{10})-O$ -, $-P(=O)(-OR_{10})-O$ -, $-O-P(=O)(-OR_{10})$;

X is independently $-R_{11}$ -, and

E is independently selected from the group consisting of $-N(R_{12})_2$, $-N(R_{12})(R_{13})$, $-S-R_{12}$, and




where $-R_{12}$ is $-CH_2CH_2-G$, where each G is independently $-Cl$, $-Br$, $-I$, $-O-S(=O)_2-CH_3$, $-O-S(=O)_2-CH_2-C_6H_5$, or $-O-S(=O)_2-C_6H_4-CH_3$;

and where R_{13} is independently $-C_{1-8}alkyl$ -, $-C_{1-8}heteroalkyl$ -, $-aryl$ -, $-heteroaryl$ -, $-C_{1-3}alkyl-aryl$ -, $-C_{1-3}heteroalkyl-aryl$ -, $-C_{1-3}alkyl-heteroaryl$ -, $-C_{1-3}heteroalkyl-heteroaryl$ -, $-aryl-C_{1-3}alkyl$ -, $-aryl-C_{1-3}heteroalkyl$ -, $-heteroaryl-C_{1-3}alkyl$ -, $-heteroaryl-C_{1-3}heteroalkyl$ -, $-C_{1-3}alkyl-aryl-C_{1-3}alkyl$ -, $-C_{1-3}heteroalkyl-aryl-C_{1-3}alkyl$ -, $-C_{1-3}alkyl-heteroaryl-C_{1-3}alkyl$ -, $-C_{1-3}alkyl-aryl-C_{1-3}heteroalkyl$ -, $-C_{1-3}heteroalkyl-heteroaryl-C_{1-3}alkyl$ -, $-C_{1-3}heteroalkyl-aryl-C_{1-3}heteroalkyl$ -, $-C_{1-3}alkyl-heteroaryl-C_{1-3}heteroalkyl$, or $-C_{1-3}heteroalkyl-heteroaryl-C_{1-3}heteroalkyl$;

and all salts and stereoisomers (including enantiomers and diastereomers) thereof.

General formula II is:



(II)

where R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , and R_8 are independently selected from the group consisting of -H, $-R_{10}$, $-O-R_{10}$, $-NO_2$, $-NH_2$, $-NH-R_{10}$, $-N(R_{10})_2$, -F, -Cl, -Br, -I, $-C(=O)-R_{10}$, $-C(=O)-O-R_{10}$, and $-O-C(=O)-R_{10}$,

where $-R_{10}$ is independently H, $-C_{1-8}$ alkyl, $-C_{1-8}$ heteroalkyl, -aryl, -heteroaryl, $-C_{1-3}$ alkyl-aryl, $-C_{1-3}$ heteroalkyl-aryl, $-C_{1-3}$ alkyl-heteroaryl, $-C_{1-3}$ heteroalkyl-heteroaryl, -aryl- $-C_{1-3}$ alkyl, -aryl- $-C_{1-3}$ heteroalkyl, -heteroaryl- $-C_{1-3}$ alkyl, -heteroaryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ heteroalkyl, or $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ heteroalkyl;

R_{20} is -H or $-CH_3$; and

R_{21} is $-R_{11}-W-X-E$,

where $-R_{11}-$ is independently $-C_{1-8}$ alkyl-, $-C_{1-8}$ heteroalkyl-, -aryl-, -heteroaryl-, $-C_{1-3}$ alkyl-aryl-, $-C_{1-3}$ heteroalkyl-aryl-, $-C_{1-3}$ alkyl-heteroaryl-, $-C_{1-3}$ heteroalkyl-heteroaryl-, -aryl- $-C_{1-3}$ alkyl-, -aryl- $-C_{1-3}$ heteroalkyl-, -heteroaryl- $-C_{1-3}$ alkyl-, -heteroaryl- $-C_{1-3}$ heteroalkyl-, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ heteroalkyl-, $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ alkyl-,


-C₁₋₃heteroalkyl-aryl-C₁₋₃ heteroalkyl-, -C₁₋₃alkyl-heteroaryl-C₁₋₃ heteroalkyl-, or
-C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ heteroalkyl-;

W is independently -C(=O)-O-, -O-C(=O)-, -C(=S)-O-, -O-C(=S)-,
-C(=S)-S-, -S-C(=S)-, -C(=O)-S-, -S-C(=O)-, -O-S(=O)₂-O-, -S(=O)₂-O-,
5 -O-S(=O)₂-, -C(=O)-NR₁₀-, -NR₁₀-C(=O)-, -O-P(=O)(-OR₁₀)-O-,
-P(=O)(-OR₁₀)-O-, -O-P(=O)(-OR₁₀)-;

X is independently -R₁₁-; and

E is independently selected from the group consisting of -N(R₁₂)₂,
-N(R₁₂)(R₁₃), -S-R₁₂,

10 and




where -R₁₂ is -CH₂CH₂-G, where each G is independently -Cl, -Br, -I,
-O-S(=O)₂-CH₃, -O-S(=O)₂-CH₂-C₆H₅, or -O-S(=O)₂-C₆H₄-CH₃;

and where R₁₃ is independently -C₁₋₈ alkyl, -C₁₋₈ heteroalkyl, -aryl,
15 -heteroaryl, -C₁₋₃alkyl-aryl, -C₁₋₃heteroalkyl-aryl, -C₁₋₃alkyl-heteroaryl,
-C₁₋₃heteroalkyl-heteroaryl, -aryl-C₁₋₃alkyl, -aryl-C₁₋₃heteroalkyl,
-heteroaryl-C₁₋₃alkyl, -heteroaryl-C₁₋₃heteroalkyl, -C₁₋₃alkyl-aryl-C₁₋₃ alkyl,
-C₁₋₃heteroalkyl-aryl-C₁₋₃ alkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃alkyl-aryl-C₁₋₃
heteroalkyl, -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃heteroalkyl-aryl-C₁₋₃
20 heteroalkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ heteroalkyl, or
-C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ heteroalkyl;

and all salts and stereoisomers (including enantiomers and diastereomers)
thereof.

General formula III is:



(III)

wherein at least one of R_{44} , R_{55} , R_3 , R_4 , R_5 , and R_8 is -V-W-X-E, and the remainder of R_{44} , R_{55} , R_3 , R_4 , R_5 , and R_8 are independently selected from the group consisting of -H, $-R_{10}$, $-O-R_{10}$, $-NO_2$, $-NH_2$, $-NH-R_{10}$, $-N(R_{10})_2$, -F, -Cl, -Br, -I, $-C(=O)-R_{10}$, $-C(=O)-O-R_{10}$, and $-O-C(=O)-R_{10}$,


where $-R_{10}$ is independently H, $-C_{1-8}$ alkyl, $-C_{1-8}$ heteroalkyl, -aryl, -heteroaryl, $-C_{1-3}$ alkyl-aryl, $-C_{1-3}$ heteroalkyl-aryl, $-C_{1-3}$ alkyl-heteroaryl, $-C_{1-3}$ heteroalkyl-heteroaryl, -aryl- $-C_{1-3}$ alkyl, -aryl- $-C_{1-3}$ heteroalkyl, -heteroaryl- $-C_{1-3}$ alkyl, -heteroaryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ heteroalkyl, or $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ heteroalkyl;

V is independently $-R_{11}-$, $-NH-R_{11}-$ or $-N(CH_3)-R_{11}-$, where $-R_{11}-$ is independently $-C_{1-8}$ alkyl-, $-C_{1-8}$ heteroalkyl-, -aryl-, -heteroaryl-, $-C_{1-3}$ alkyl-aryl-, $-C_{1-3}$ heteroalkyl-aryl-, $-C_{1-3}$ alkyl-heteroaryl-, $-C_{1-3}$ heteroalkyl-heteroaryl-, -aryl- $-C_{1-3}$ alkyl-, -aryl- $-C_{1-3}$ heteroalkyl-, -heteroaryl- $-C_{1-3}$ alkyl-, -heteroaryl- $-C_{1-3}$ heteroalkyl-, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ heteroalkyl-, $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ heteroalkyl-, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ heteroalkyl-, or $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ heteroalkyl-;

W is independently -C(=O)-O-, -O-C(=O)-, -C(=S)-O-, -O-C(=S)-, -C(=S)-S-, -S-C(=S)-, -C(=O)-S-, -S-C(=O)-, -O-S(=O)₂-O-, -S(=O)₂-O-, -O-S(=O)₂-, -C(=O)-NR₁₀-, -NR₁₀-C(=O)-, -O-P(=O)(-OR₁₀)-O-, -P(=O)(-OR₁₀)-O-, -O-P(=O)(-OR₁₀)-;

5 X is independently -R₁₁-; and

E is independently selected from the group consisting of -N(R₁₂)₂, -N(R₁₂)(R₁₃), -S-R₁₂, and




10 where -R₁₂ is -CH₂CH₂-G, where each G is independently -Cl, -Br, -I, -O-S(=O)₂-CH₃, -O-S(=O)₂-CH₂-C₆H₅, or -O-S(=O)₂-C₆H₄-CH₃;

and where R₁₃ is independently -C₁₋₈ alkyl, -C₁₋₈ heteroalkyl, -aryl, -heteroaryl, -C₁₋₃alkyl-aryl, -C₁₋₃heteroalkyl-aryl, -C₁₋₃alkyl-heteroaryl, -C₁₋₃heteroalkyl-heteroaryl, -aryl-C₁₋₃alkyl, -aryl-C₁₋₃heteroalkyl, -heteroaryl-C₁₋₃alkyl, -heteroaryl-C₁₋₃heteroalkyl, -C₁₋₃alkyl-aryl-C₁₋₃ alkyl, -C₁₋₃heteroalkyl-aryl-C₁₋₃ alkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃alkyl-aryl-C₁₋₃ heteroalkyl, -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃heteroalkyl-aryl-C₁₋₃ heteroalkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ heteroalkyl, or -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ heteroalkyl;

20 and all salts and stereoisomers (including enantiomers and diastereomers) thereof.


It will be appreciated that, in general formula I above, the acridine nucleus is the anchor moiety, the -V-W-X- group(s) comprises the frangible linker, and the E group(s) is the effector group. Similarly, in general formula III above, the psoralen nucleus is the anchor moiety, the -V-W-X- group(s) comprises the frangible linker, and the E group(s) is the effector group. General formula II is a subset of general formula I.

An exemplary compound of the invention is the structure below,
designated IV:



IV

In IV, a 2-carbomethoxyacridine ring system serves as the anchor moiety via intercalation. A bis (chloroethyl) amine group serves as the effector moiety, which can alkylate nucleic acid; the nitrogen mustard hydrolyzes if it does not react with nucleic acid. The linker is -NH-CH₂CH₂-C(=O)-O-CH₂CH₂-. In aqueous solution at physiological pH, this ester-containing linker hydrolyzes within hours. Changing the pH of the solution changes the rate at which the linker hydrolyzes; for the corresponding alcohol analog of IV (where the -Cl atoms of IV are replaced with -OH groups), $\leq 1\%$ hydrolysis of the ester linkage is observed at pH 3 after 100 minutes at 37 °C; at pH 8, more than 50% hydrolysis of the ester linkage is observed after 100 minutes at 37 °C. The resulting hydrolysis products of IV are N-(2-carbomethoxy-9-acridinyl)- β -alanine and triethanolamine:




where the 2-carbomethoxyacridine bears β -alanine as a linker fragment, and the effector breakdown product bears an ethanol group as a linker fragment.


At physiological pH values, the carboxylate of the β -alanine will be negatively charged, a feature which decreases the tendency of the attached 2-carbomethoxyacridine group to intercalate into a negatively charged nucleic acid molecule. This lowers the mutagenicity of N-(2-carbomethoxy-9-acridinyl)- β -alanine relative to 9-aminoacridine. This potential for lowering the mutagenicity of the anchor fragment illustrates one advantage provided by the frangible linker.

Another advantage of the frangible linker in compounds similar to IV is that the hydrolysis rate can be adjusted by varying the length of the linker arm between the 9-aminoacridine anchor moiety and the ester function. As described in Example 7 and Tables III and IV below, an increase in the number of methylene groups between the aminoacridine anchor and the ester group results in a decrease in the amount of hydrolysis seen in aqueous solution, at pH 8, 37 °C, for diol analogs of certain compounds of the invention (where the -Cl atoms of the mustards are replaced with -OH groups).


Examples of the compounds of the invention are given below, as illustration and not as any limitation on the invention.




IV




VI




XI




VII




XII




VIII




V




IX




X



XIII



XIV



XV

5

Applications

10

Examples of uses of the compounds of the invention include, but are not limited to: addition of the compounds of the invention in solid or solution form to biological materials, to inactivate pathogens present in the biological materials; immersion or other treatment of a material for biological use in a solution of the compounds of the invention, to inactivate pathogens present in or on the material; and inclusion of compounds of the invention in targeted liposomes, to direct the compounds to particular cells in order to damage the nucleic acid of those cells.

15

20

It should be noted that while the compounds of the invention are designed to hydrolyze under certain conditions, they are stable under other conditions. It is desirable for the frangible linker and the effector group(s) to be relatively stable under certain conditions used for storage. Examples of manners in which the compounds may be stored include, but are not limited to, dry solids, oils with low water content, frozen aqueous solutions, frozen non-aqueous solutions, suspensions, and solutions which do not permit hydrolysis of the frangible linker or the effector group(s), for example liquid non-aqueous solutions. The compounds may be stored at temperatures at or below 0 °C (e.g., in a freezer), or at temperatures above 0 °C (e.g., in a refrigerator or at ambient temperatures). The compounds preferably are stable under the storage conditions for a period of

between three days and one year, between one week and one year, between one month and one year, between three months and one year, between six months and one year, between one week and six months, between one month and six months, between three months and six months, between one week and three months, or
5 between one month and three months. The stability of the compounds will be determined both by the temperature at which they are stored, and by the state in which they are stored (e.g., non-aqueous solution, dry solid).

Conditions for Pathogen Inactivation

Conditions for treating biological materials with a pathogen inactivating
10 compound may be selected based on the selected material and the inactivating compound. Typical concentrations of pathogen inactivating compound for the treatment of biological materials such as blood products are on the order of about 0.1 μ M to 5 mM, for example about 500 μ M. For example, a concentration of pathogen inactivating compound may be used which is sufficient to inactivate at
15 least about 1 log, or at least about 2 logs, or for example, at least about 3 to 6 logs of a pathogen in the sample. In one embodiment, the pathogen inactivating compound produces at least 1 log kill at a concentration of no greater than about 500 μ M, more preferably at least 3 logs kill at no greater than 500 μ M concentration. In another non-limiting example, the pathogen inactivating
20 compound may have at least 1 log kill, and preferably at least 6 logs kill at a concentration of about 0.1 μ M to about 3 mM.

Incubation of blood products with the pathogen inactivating compound can be conducted for example, for about 5 minutes to 72 hours or more, or about 1 to 48 hours, for example, about 1 to 24 hours, or, for example, about 8 to 20 hours.
25 For red blood cells, the incubation is typically conducted at a temperature of about 2°C to 37°C, preferably about 18°C to 25°C. For platelets, the temperature is preferably about 20 to 24°C. For plasma, the temperature may be about 0 to 60°C, typically about 0-24°C. The pH of the material being treated is preferably about 4 to 10, more preferably about 6 to 8.

One embodiment of the invention encompasses compounds and methods for use in inactivating pathogens in blood or blood products, and a preferred set of storage conditions for this purpose would be those conditions that allow the convenient storage and use of the compounds at blood banks.

5 Under the conditions used for pathogen inactivation in or on a material, the frangible linker and effector group(s) will undergo hydrolysis or reaction. The hydrolysis, of both the frangible linker and the effector groups(s), preferably is slow enough to enable the desired amount of pathogen inactivation to take place. The time required for pathogen inactivation may be, for example, about 5 minutes
10 to 72 hours.

Treatment of Red Blood Cells

Preferably, treatment of red blood cell containing materials with the pathogen inactivating compound does not damage red blood cell function or modify red blood cells after treatment. The lack of a substantially damaging
15 effect on red blood cell function may be measured by methods known in the art for testing red blood cell function. For example, the levels of indicators such as intracellular ATP (adenosine 5'-triphosphate), intracellular 2,3-DPG (2,3-diphosphoglycerol) or extracellular potassium may be measured, and compared to an untreated control. Additionally hemolysis, pH, hematocrit, hemoglobin,
20 osmotic fragility, glucose consumption and lactate production may be measured.

Methods for determining ATP, 2,3-DPG, glucose, hemoglobin, hemolysis, and potassium are available in the art. See for example, Davey *et al.*, *Transfusion*, 32:525-528 (1992), the disclosure of which is incorporated herein. Methods for determining red blood cell function are also described in Greenwalt *et al.*, *Vox Sang*, 58:94-99 (1990); Hogman *et al.*, *Vox Sang*, 65:271-278 (1993); and Beutler
25 *et al.*, *Blood*, Vol. 59 (1982) the disclosures of which are incorporated herein by reference. Extracellular potassium levels may be measured using a Ciba Corning Model 614 K⁺/Na⁺ Analyzer (Ciba Corning Diagnostics Corp., Medford, MA). The pH can be measured using a Ciba Corning Model 238 Blood Gas Analyzer
30 (Ciba Corning Diagnostics Corp., Medford, MA).

Binding of species such as IgG, albumin, and IgM to red blood cells also may be measured using methods available in the art. Binding of molecules to red blood cells can be detected using antibodies, for example to acridine and IgG. Antibodies for use in assays can be obtained commercially, or can be made using methods available in the art, for example as described in Harlow and Lane, "Antibodies, a Laboratory Manual, Cold Spring Harbor Laboratory," 1988, the disclosure of which is incorporated herein. For example, anti-IgG is commercially available from Caltag, Burlingame, CA; Sigma Chemical Co., St. Louis, MO and Lampire Biological Laboratory, Pipersville, PA.

In a method of treatment of a material comprising red blood cells with the pathogen inactivating, preferably the level of extracellular potassium is not greater than 3 times, more preferably no more than 2 times the amount exhibited in the untreated control after 1 day. In another embodiment, preferably, hemolysis of the treated red blood cells is less than 3% after 28 day storage, more preferably less than 2% after 42 day storage, and most preferably less than or equal to about 1% after 42 day storage at 4°C.

Biological Materials

A variety of biological materials may be treated with a pathogen inactivating compound. Biological materials include blood products such as whole blood, packed red blood cells, platelets and fresh or frozen plasma. Blood products further encompass plasma protein portion, antihemophilic factor (Factor VIII), Factor IX and Factor IX complex, fibrinogens, Factor XIII, prothrombin and thrombin, immunoglobulins (such as IgG, IgA, IgD, IgE and IgM and fragments thereof), albumin, interferon, and lymphokines. Also contemplated are synthetic blood products.

Other biological materials include vaccines, recombinant DNA produced proteins and oligopeptide ligands. Also encompassed are clinical samples such as urine, sweat, sputum, feces, spinal fluid. Further encompassed are synthetic blood or blood product storage media.

Reducing the Concentration of Compounds in Materials after Treatment

The concentration of the pathogen inactivating compound in a biological material, such as a blood product, can be reduced after the treatment. Methods and devices which may be used are described in PCT US96/09846; U.S. Serial
5 No. 08/779,830, filed January 6, 1997; and in the co-filed application, "Methods and Devices for the Reduction of Small Organic Compounds from Blood Products", Serial No. ___, Attorney Docket No. 2000440, filed January 6, 1998, the disclosures of each of which are incorporated herein by reference in their entirety.

10 *Quenching*

In another embodiment the compounds of the invention may be used in combination with a quencher. Methods for quenching undesired side reactions of pathogen inactivating compounds in biological materials are described in the
15 cofiled U.S. Provisional Application Serial No. ___, filed January 6, 1998, Attorney Docket No. 282173000600, "Methods for Quenching Pathogen Inactivators in Biological Materials," the disclosure of which is incorporated herein. Disclosed in the cofiled application are methods for quenching undesired side reactions of a pathogen inactivating compound that includes a functional
20 group which is, or which is capable of forming, an electrophilic group. In this embodiment, the material is treated with the pathogen inactivating compound and a quencher, wherein the quencher comprises a nucleophilic functional group that is capable of covalently reacting with the electrophilic group. Preferred quenchers are thiols, such as glutathione.

25 EXAMPLES

The following specific examples are presented to illustrate the preparative methods for representative compounds useful in the method of this invention, to provide
30 relevant data regarding the compounds useful to the practitioner, and to illustrate the

manner in which the effectivity of the compounds is determined, and are not to be construed as limiting the scope of the invention. All NMR spectra were recorded on a Varian 200 MHz instrument in CDCl₃ unless otherwise noted; chemical shifts are reported versus tetramethylsilane (TMS). IR spectra were recorded with a Perkin Elmer FTIR. HPLC was carried out with a YMC C8 column in a gradient mode using 5 mM aq. H₃PO₄ as mobile phase A and 5 mM CH₃CN as mobile phase B. Samples were prepared in DMSO or ethanol and kept at ≤ 15 °C prior to injection.

Table II indicates the designation of compound number used for the various compounds.

Table II

COMPOUND NUMBER	CHEMICAL NAME
IV	β -alanine, N-(2-carbomethoxyacridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester
V	β -alanine, N-(acridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester
VI	4-aminobutyric acid N-[(2-carbomethoxyacridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester
VII	5-aminovaleric acid N-[(2-carbomethoxyacridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester
VIII	β -alanine, N-(2-carbomethoxyacridin-9-yl), 3-[bis(2-chloroethyl)amino]propyl ester
IX	β -alanine, N-(4-methoxyacridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester
X	β -alanine, N-(3-chloro-4-methylacridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester
XI	β -alanine, [N,N-bis(2-chloroethyl)], 3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl ester

COMPOUND NUMBER	CHEMICAL NAME
XII	β -alanine, [N,N-bis(2-chloroethyl)], 2-[(6-chloro-2-methoxyacridin-9-yl)amino]ethyl ester
XIII	β -alanine, N-(6-chloro-2-methoxyacridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester
XIV	[N,N-bis(2-chloroethyl)]-2-aminoethyl 4,5',8-trimethyl-4'-psoralenacetate
XV	β -alanine, N-(acridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl amide

Example 1

5 Synthesis of β -alanine, N-(2-carbomethoxyacridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester dihydrochloride (Compound IV,)

Step A. β -Alanine, N-(*tert*-butoxycarbonyl), 2-[bis(2-hydroxyethyl)amino]ethyl ester

10 To a stirred solution of N-(*tert*-butoxycarbonyl)- β -alanine (20.3 g, 107 mmol) and 4-methylmorpholine (13.0 mL, 12.0 g, 119 mmol) in dry THF (200 mL) at -15 °C under N₂ was added isobutyl chloroformate (13.9 mL, 14.6 g, 107 mmol) resulting in the immediate formation of a white precipitate (4-methylmorpholine•HCl). The reaction mixture was stirred at -15 °C for 5 min. followed by the transfer of the reaction mixture to

15 a flask containing a stirred solution of triethanolamine (48.3 g, 324 mmol) in dry THF (150 mL) at -15 °C. The reaction mixture was allowed to warm to 23 °C and stirred for an additional 1.5 h. followed by removal of the precipitate by vacuum filtration. The THF was then removed *in vacuo* from the filtrate and the remaining viscous yellow oil was partitioned between water (500 mL) and EtOAc (5 x 150 mL). The combined

20 organic layers were dried over Na₂SO₄. Removal of solvent *in vacuo* gave 25.8 g (75%) of the desired product, β -alanine, N-(*tert*-butoxycarbonyl), 2-[bis(2-hydroxyethyl)amino]ethyl ester, as a pale yellow oil. ¹H NMR: δ 5.32 (br s, 1 H), 4.18 (t,

$J = 5.4$ Hz, 2H), 3.58 (t, $J = 5.1$ Hz, 4 H), 3.37-3.23 (m, 2H), 2.80 (t, $J = 5.4$ Hz, 2H), 2.69 (t, $J = 5.1$ Hz, 4 H), 2.51 (t, $J = 6.0$ Hz, 2 H), 1.41 (s, 9 H) The hydroxyl protons were not observed. ^{13}C NMR: δ 173.0, 156.4, 79.8, 63.3, 60.2, 57.3, 54.1, 36.7, 35.3, 28.8.

5 Step B. β -Alanine, N-(*tert*-butoxycarbonyl), 2-[bis(2-*tert*-butyldimethylsilyloxyethyl)amino]ethyl ester

A stirred solution of the β -alanine, N-(*tert*-butoxycarbonyl), 2-[bis(2-hydroxyethyl)amino]ethyl ester from step A (22.7 g, 70.9 mmol) and imidazole (11.1 g, 163 mmol) in acetonitrile (70 mL) under N_2 was cooled to 0 °C. *Tert*-butyldimethylsilyl chloride (534 mg, 3.54 mmol) was then added and the reaction mixture was stirred for an additional 5 min. at 0 °C. The reaction mixture was allowed to warm to 23 °C and stirred for 2 h followed by removal of the resultant white precipitate (imidazole \cdot HCl) by vacuum filtration. The acetonitrile was removed *in vacuo* from the filtrate and the remaining material was partitioned between saturated brine (600 mL) and EtOAc (3 x 200 mL). The combined organic layers were dried over Na_2SO_4 . Removal of solvent *in vacuo* gave 35.2 g (90%) of the desired product, β -alanine, N-(*tert*-butoxycarbonyl), 2-[bis(2-*tert*-butyldimethylsilyloxyethyl)amino]ethyl ester, as a yellow oil. ^1H NMR : δ 5.29 (br s, 1 H), 4.14 (t, $J = 6.0$ Hz, 2 H), 3.65 (t, $J = 6.3$ Hz, 4 H), 3.37 (apparent q, 2 H), 2.85 (t, $J = 6.0$ Hz, 2 H), 2.71 (t, $J = 6.3$ Hz, 4 H), 2.49 (t, $J = 5.9$ Hz, 2 H), 1.42 (s, 9 H), 0.88 (s, 18 H), 0.03 (s, 12 H); ^{13}C NMR: δ 172.7, 156.3, 79.7, 63.3, 62.4, 57.7, 54.3, 36.7, 35.3, 28.9, 26.4, 18.7, -4.9.

Step C. β -Alanine, 2-[bis(2-*tert*-butyldimethylsilyloxyethyl)amino] ethyl ester

To a flask containing β -alanine, N-(*tert*-butoxycarbonyl), 2-[bis(2-*tert*-butyldimethylsilyloxyethyl)amino]ethyl ester from step B (3.01 g, 5.48 mmol) was added neat trifluoroacetic acid (5 mL) resulting in the evolution of CO_2 gas. The reaction mixture was stirred for 5 min. and the trifluoroacetic acid was removed *in vacuo*. The remaining material was partitioned between saturated NaHCO_3 (100 mL) and EtOAc (3 x 30 mL). The combined organic layers were dried over Na_2SO_4 . Removal of solvent *in*

vacuo gave 2.45 g (100%) of the desired product, β -alanine, 2-[bis(2-*tert*-butyldimethylsilyloxyethyl)amino]ethyl ester, as a pale yellow oil. ^1H NMR: δ 4.12 (t, J = 6.0 Hz, 2 H), 3.63 (t, J = 6.4 Hz, 4 H), 2.96 (t, J = 6.2 Hz, 2 H), 2.84 (t, J = 6.0 Hz, 2 H), 2.69 (t, J = 6.4 Hz, 4 H), 2.44 (t, J = 6.2 Hz, 2 H), 0.86 (s, 18 H), 0.03 (s, 12 H). The amine protons were not observed. ^{13}C NMR (CDCl_3): δ 173.0, 63.4, 62.6, 57.9, 54.4, 38.4, 38.1, 26.4, 18.7, -4.9.

Step D. β -Alanine, N-(2-carbomethoxyacridin-9-yl), 2-[bis(2-hydroxyethyl)amino]ethyl ester

The β -alanine, 2-[bis(2-*tert*-butyldimethylsilyloxyethyl)amino]ethyl ester (736 mg, 1.64 mmol) was reacted with methyl 9-methoxyacridine-2-carboxylate (669 mg, 2.50 mmol) by stirring in 10 mL of CHCl_3 for 12.5 h at room temperature. The precipitate (acridone) was then filtered off and the filtrate partitioned between saturated aqueous NaHCO_3 (100 mL) and CHCl_3 (3 x 35 mL). The combined organic layers were dried over Na_2SO_4 and concentrated *in vacuo* to give 1.61 g of viscous brown oil. Deprotection of the resultant diol was carried out by dissolving the crude intermediate in 3.0 mL of THF under N_2 and, upon cooling to 0 $^\circ\text{C}$, treating with HF/pyridine (1.0 mL). The solution was allowed to warm to room temperature with stirring for 1 h. The volatiles were removed *in vacuo* and the residue was partitioned between saturated aqueous NaHCO_3 (100 mL) and CHCl_3 (3 x 35 mL). The combined organic layers were dried and concentrated to give 649 mg of a brownish yellow solid. Preparative TLC (C-18, CH_3CN) gave a 20 % yield of the desired diol, β -alanine, N-(2-carbomethoxyacridin-9-yl), 2-[bis(2-hydroxyethyl)amino]ethyl ester (>80% pure by HPLC); ^1H NMR: δ 8.82 (s, 1 H), 8.21-7.94 (m, 2 H), 7.94-7.72 (m, 2 H), 7.59 (apparent t, 1 H), 7.23 (apparent t, 1 H), 4.30-4.18 (m, 2 H), 4.18-4.05 (m, 2 H), 3.89 (s, 3 H), 3.69-3.50 (m, 4 H), 2.92-2.73 (m, 4 H), 2.73-2.55 (m, 4 H). The amine and hydroxyl protons were not observed.

Step E. β -Alanine, N-(2-carbomethoxyacridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester dihydrochloride

Conversion of β -alanine, N-(2-carbomethoxyacridin-9-yl), 2-[bis(2-hydroxyethyl)amino]ethyl ester to the dichloro compound was achieved by a method similar to that of Peck, et al. (*J. Am. Chem. Soc.* 1959, 81: 3984). A yellow solution of the product from step D (41 mg, 0.090 mmol) in neat SOCl_2 (6 mL) was stirred at room temperature for 20 hours. The SOCl_2 was then removed *in vacuo* to give a yellow solid (dihydrochloride salt). The material was then partitioned between saturated NaHCO_3 (50 mL) and CH_2Cl_2 (3 x 20 mL). The combined organic layers were dried over Na_2SO_4 . Removal of solvent *in vacuo* gave 35.4 mg of the dichloro compound free base as an orange gum. ^1H NMR: δ 8.82 (s, 1 H), 8.20-7.83 (m, 4 H), 7.5 (apparent t, 1 H), 7.25 (apparent t, 1 H), 4.36-4.15 (m, 4 H), 3.93 (s, 3 H), 3.48 (t, $J = 6.9$ Hz, 4 H), 3.06-2.77 (m, 4 H), 2.86 (t, $J = 6.9$ Hz, 4 H). The amine proton was not observed. ^{13}C NMR: δ 172.3, 166.6, 155.2, 146.5, 144.6, 133.1, 131.6, 128.7, 124.6, 124.3, 116.1, 114.3, 63.7, 57.2, 53.5, 52.9, 46.3, 42.5, 35.2. No other carbons were observed. The HCl salt was precipitated from CH_2Cl_2 by addition of 1 M HCl in ether to give β -alanine, N-(2-carbomethoxyacridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester dihydrochloride (Compound IV,) as a yellow solid (81 % pure by HPLC).

β -Alanine, N-(acridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester dihydrochloride, (Compound V) was prepared in a similar manner. Thus using 9-methoxyacridine in place of methyl 9-methoxyacridine-2-carboxylate in Step D, the intermediate diol was obtained (7.1%) as a yellow oil (74% pure by HPLC). ^1H NMR: δ 8.14 (d, $J = 7.5$ Hz, 2 H), 7.93 (d, $J = 8.6$ Hz, 2 H), 7.52 (apparent t, 2 H), 7.23 (apparent t, 2 H), 4.36-4.08 (m, 4 H), 3.76-3.5 (m, 4 H), 3.08-2.60 (m, 8 H). The amine and hydroxyl protons were not observed.

A solution of the intermediate diol (37.3 mg, 0.0793 mmol) in thionyl chloride (4.0 mL) was stirred at 23 °C for 7.5 h. The thionyl chloride was removed *in vacuo* to give a yellow oil. The material was dissolved in ethanol (~4 mL) and the solvent removed *in vacuo*. The material was then dissolved in CH_2Cl_2 (4 mL) and solvent removed *in vacuo*; this step was repeated twice. The material was then triturated with

hexane (3 x 4 mL) to give 40.0 mg (42 % pure by HPLC) of the product in the form of a yellow hygroscopic glassy solid. Some of the material was converted to the free amine for analytical purposes by partitioning between saturated NaHCO_3 and CH_2Cl_2 followed by drying the combined organic layers over Na_2SO_4 and removal of the solvent *in vacuo*.

^1H NMR: δ 8.21-8.00 (m, 4 H), 7.66 (apparent t, 2 H), 7.38 (apparent t, 2 H), 4.26-4.12 (m, 2 H), 4.12-3.98 (m, 2 H), 3.43 (t, $J = 6.9$ Hz, 4 H), 2.96-2.68 (m, 8 H) The amine proton was not observed.

Following the above procedure but replacing N-(*tert*-butoxycarbonyl)- β -alanine with N-(*tert*-butoxycarbonyl)-4-aminobutyric acid led to the preparation of 4-aminobutyric acid N-[(2-carbomethoxyacridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester dihydrochloride, Compound VI (78% pure by HPLC). ^1H NMR: δ 8.89 (s, 1), 8.12 (apparent t, 2), 7.93-7.80 (m, 2), 7.59 (apparent q, 1), 7.36-7.20 (m, 1), 4.16 (t, 2, $J = 5.7$ Hz), 4.07-3.92 (m, 2), 3.97 (s, 3), 3.46 (t, 4, $J = 6.9$ Hz), 2.93-2.80 (m, 6), 2.60 (t, 2, $J = 6.5$ Hz), 2.29-2.12 (m, 2). The amine proton was not observed.

Example 2

Substituting the triethanolamine in Example 1, Step A with 3-[N,N-Bis(2-*tert*-butyldimethylsilyloxyethyl)]aminopropanol, and then continuing from step C, led to the preparation of β -alanine, N-(2-carbomethoxy-acridin-9-yl), 3-[bis(2-chloroethyl)amino]propyl ester dihydrochloride, Compound VIII, (63% pure by HPLC).

^1H NMR : δ 8.91 (s, 1), 8.20-7.93 (m, 4), 7.18 (apparent t, 1), 7.39 (apparent t, 1), 4.30 (m, 4), 3.96 (s, 3), 3.48 (t, 4, $J = 6.9$ Hz), 2.88-2.60 (m, 2), 2.83 (t, 4, $J = 6.9$ Hz), 2.62 (t, 2, $J = 6.7$ Hz), 1.85-1.68 (m, 2) The amine proton was not observed.

Example 3

The compounds synthesized in Example 1 can also be prepared by the following method:

Synthesis of β -alanine, N-(acridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester dihydrochloride (Compound V): Method II

5

Step A: β -Alanine, N-(acridin-9-yl), methyl ester hydrochloride

9-Chloroacridine (11.7 g, Organic Synthesis, Coll. Vol III, pg 57), β -alanine methyl ester hydrochloride (9.9 g) and sodium methoxide (3.26 g) were combined and 60
10 mL of methanol was added. The mixture was stirred with a magnetic stirrer and refluxed for 5.5 h . Heat was removed and the suspension was filtered while warm (≤ 35 °C). The solid salts were rinsed with about 10 mL of additional methanol and the combined dark green filtrate was concentrated to give 21 g of a moist greenish-yellow solid.

The solid was dissolved in 350 mL of boiling 2-propanol and allowed to
15 crystallize at room temperature. The resulting crystals were rinsed with about 15 mL of 2-propanol and 15 mL of hexane, then air dried to give 15.5 g of bright yellow product, β -alanine, N-(acridin-9-yl), methylester hydrochloride, (yield 78.5%). ^1H NMR: δ 1.9 (br s, 2H); 3.24 (t, J=7.0 Hz, 2H); 3.76 (s, 3H); 4.45 (br s, 2H); 7.23 (app. t, J=8 Hz, 2H); 7.49 (app. t, J=8 Hz, 2H); 8.11 (d, J=8.4 Hz, 2H); 8.30 (d, J=8.4 Hz, 2H); 9.68 (br s, 0.5
20 H). IR: 1574 (s), 1691 (s), 1726 (s), 2336 (m), 2361 (m), 3227 (m).

Step B: β -Alanine, N-(acridin-9-yl), 2-[bis(2-hydroxyethyl)amino]ethyl ester dihydrochloride

The β -alanine, N-(acridin-9-yl), methyl ester hydrochloride, from Step A, (5.00
25 g) was partitioned between toluene (750 mL), saturated aqueous Na_2CO_3 (200 mL) and H_2O (50 mL). The aqueous layer was extracted again with toluene (3 x 250 mL) and the organic layers were combined and washed with saturated aqueous Na_2CO_3 (50 mL). The volume of toluene was reduced to about 100 mL by rotary evaporation. Triethanolamine (30 mL) was then added to form a partially immiscible system. A solution of NaOMe (50

mg) in MeOH (2mL) was then added. Solvents were quickly removed from the reaction mixture by rotary evaporation with agitation at room temperature. After the solvent was removed the reaction mixture was left under vacuum for another 1-1.5h to give a syrupy solution.

5 The crude mixture was partitioned between CH₂Cl₂ (200 mL) and brine (200 mL) to remove excess triethanolamine. The brine layer was extracted with CH₂Cl₂ (5 x 100 mL). The organic layers were combined and washed with brine (50 mL) then extracted with 0.5M HCl (2 x 100 mL). The aqueous acid layers were combined and washed with
10 CH₂Cl₂ (50 mL). The acid solution was made basic with powdered K₂CO₃(s) in the presence of CH₂Cl₂ (200 mL). The organic layer was separated and the aqueous layer was extracted again with CH₂Cl₂ (5 x 100 mL). The combined organic layers were washed with brine (50 mL), dried with anhydrous Na₂SO₄(s), and stripped to give crude diol free amine (5.02 g), a sticky yellow gum. This material was identical by NMR to
15 that prepared in Example 1 by an alternate procedure.

A portion of the above crude (0.400g) was vigorously stirred with isopropanol (100 mL) and acidified with 1 M HCl in ether. The slurry was chilled and the first precipitate was discarded. After removing half the solvent the second set of crystals gave β-alanine, N-(acridin-9-yl), 2-[bis(2-hydroxyethyl)amino]ethyl ester dihydrochloride as a
20 bright yellow crystalline solid (0.200g) >95 % pure by HPLC. ¹H NMR: δ 8.11 (apparent t, 4 H), 7.69 (apparent t, 2 H), 7.41 (apparent t, 2 H), 4.23 (t, J = 5.4 Hz, 2 H), 4.03 (t, J = 5.9 Hz, 2 H), 3.58 (t, J = 5.2 Hz, 4 H), 2.73 (t, J = 5.4 Hz, 2 H), 2.70 (t, J = 5.9 Hz, 2 H) 2.68 (t, J = 5.2 Hz, 4 H). The amine and hydroxyl protons were not observed.
¹³C NMR: δ 173.3, 151.7, 149.4, 130.5, 129.5, 124.0, 123.4, 118.4, 63.5, 60.1, 57.3,
25 54.0, 46.6, 35.8.

Step C: β-Alanine, N-(acridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester dihydrochloride

SOCl₂ (0.5 ml) was added to a stirred suspension of β-alanine, N-(acridin-9-yl), 2-[bis(2-hydroxyethyl)amino]ethyl ester dihydrochloride from Step B (113 mg, 0.24 mmol) in CH₃CN (0.5 mL). The resultant yellow solution was stirred at 23 °C for 16 h followed by removal of the volatiles *in vacuo*. The remaining orange oil was dissolved in EtOH (~2 mL) and the EtOH was removed *in vacuo* to give a yellow solid. The material was then triturated with hexane (2 x 3 mL). Removal of residual solvents *in vacuo* gave 123 mg of the desired material, β-alanine, N-(acridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester dihydrochloride, (93 % pure by HPLC) as a yellow solid. ¹H NMR: δ 8.09 (apparent t, J = 8.8 Hz, 4 H), 7.66 (apparent t, J = 7.6 Hz, 2 H), 7.38 (apparent t, J = 7.7 Hz, 2 H), 4.14 (t, J = 5.9 Hz, 2 H), 4.00 (t, J = 5.8 Hz, 2 H), 3.43 (t, J = 6.9 Hz, 4 H), 2.87 (t, J = 6.9 Hz, 4 H), 2.77 (t, J = 5.9 Hz, 2 H), 2.69 (t, J = 5.8 Hz, 2 H). The amine proton was not observed. ¹³C NMR : δ 173.0, 151.5, 149.4, 130.5, 129.6, 124.1, 123.4, 118.6, 63.5, 57.3, 53.5, 46.7, 42.5, 35.7. IR (KBr pellet of HCl salt): 3423, 3236, 2939, 2879, 1736, 1634, 1586, 1572, 1540, 1473, 1272, 1173 cm⁻¹.

Example 4

β-alanine, N-(4-methoxy-acridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester dihydrochloride, Compound IX.

β-alanine, N-(4-methoxy-acridin-9-yl), methyl ester was prepared by mixing 1.4 g (5.84 mmol) of 4,9-dimethoxyacridine, 0.89 g (6.42 mmol) of β-alanine methyl ester hydrochloride and 20 ml of methanol and then heating to reflux for 12h under N₂. The reaction was then concentrated *in vacuo*, dissolved in CHCl₃-isopropanol (50 ml, 4:1 v/v), and washed with 50% NH₄OH (2 x 25 ml) and brine (1 x 25 ml). The organic layer was dried with Na₂SO₄ and concentrated *in vacuo* to yield 1.24 g (68%) of the methyl ester (>74% purity by HPLC) as a yellow oil; R_f (SiO₂, ethyl acetate) = 0.25; IR (thin film): 3363, 2947, 1730, 1611, 1573, 1518, 1484, 1463, 1423, 1420, 1246, 1170, 1081 cm⁻¹; ¹H NMR: δ 2.70 (t, 2H, J=5.7 Hz), 3.74 (s, 3H), 4.00 (t, 2H, J=6.3 Hz), 4.11 (s,

3H), 6.98 (d, 1H, $J=7.4$ Hz), 7.36 (m, 2H), 7.65 (m, 2H), 8.12 (d, 2H, $J=8.5$ Hz); ^{13}C NMR): δ 35.7, 46.9, 52.3, 56.5, 107.2, 115.3, 119.8, 123.5, 124.1, 130.0, 151.4, 173.6.

This was converted to the diol under conditions described in Example 3, Step B to afford 647 mg of a yellow oil. HPLC analysis of the crude mixture indicated a yield of 85% ($\lambda = 278$ nm); R_f (SiO₂, 20% methanol-ethyl acetate) = 0.17; IR (thin film): 3337, 2947, 2828, 1726, 1616, 1569, 1522, 1484, 1463, 1420, 1348, 1250, 1174, 1127, 1081, 1043 cm^{-1} ; ^1H NMR: δ 2.7 (m, 8H), 3.55 (m, 4H), 3.97-4.08 (m, 2H), 4.08 (s, 3H), 4.19 (t, 2H, $J=5.5$ Hz), 6.96 (d, 1H, $J=7.4$ Hz), 7.29 (m, 2H), 7.61 (m, 2H), 8.10 (m, 2H); ^{13}C NMR: δ 36.0, 46.9, 53.7, 56.4, 57.1, 60.1, 63.3, 107.4, 115.7, 119.1, 119.6, 123.2, 123.5, 123.9, 128.5, 130.0, 140.8, 147.4, 151.6, 151.7, 154.3, 173.3.

This was converted to β -alanine, N-(4-methoxy-acridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester dihydrochloride with thionyl chloride as described in Example 3, Step C. Flash filtration (SiO₂) of the crude product using ethyl acetate followed by 10% methanol-ethyl acetate gave 58 mg of a yellow oil after apparent on-column degradation of some product; R_f (SiO₂, ethyl acetate) = 0.26; IR (thin film): 3405, 2955, 2828, 1726, 1616, 1577, 1518, 1463, 1416, 1348, 1246, 1174, 1123, 1081, 1013 cm^{-1} ; ^1H NMR: δ 2.69-2.99 (m, 8H), 3.45 (t, 4H, $J=6.7$ Hz), 4.03 (m, 2H), 4.09 (s, 3H), 4.16 (t, 2H, $J=5.9$ Hz), 6.97 (d, 1H, $J=7.7$ Hz), 7.32 (m, 2H), 7.65 (m, 2H), 8.12 (d, 2H, $J=8.7$ Hz).

The dihydrochloride salt could be isolated in crude form by concentrating the reaction *in vacuo* with azeotropic removal of excess thionyl chloride (2 x 5 ml toluene). HPLC analysis indicated complete consumption of the starting material and 4-methoxy acridone ($R_T=22.3$ min) to be the major impurity. ^1H NMR (CD₃OD): δ 3.18 (t, 2H, $J=6.4$ Hz), 3.71 (m, 6H), 4.04 (m, 4H), 4.18 (s, 3H), 4.51 (m, 2H), 7.17 (m, 2H), 7.56 (m, 2H), 7.91-8.15 (m, 2H), 8.55 (d, 1H, $J=8.8$ Hz).

Similarly prepared from 3-chloro-9-methoxy-4-methylacridine was β -alanine, N-(3-chloro-4-methylacridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester dihydrochloride,

Compound X. ^1H NMR of the free base: δ 7.96-8.17 (m, 3H), 7.29-7.52 (m, 3H), 4.19 (t, $J = 5.8$ Hz, 2H), 4.00 (s, 3H), 3.89 (t, $J = 5.1$ Hz, 2H), 3.47 (t, $J = 6.8$ Hz, 4H), 2.91 (t, $J = 6.8$ Hz, 4H), 2.83 (t, $J = 5.8$ Hz, 2H), 2.67 (t, $J = 5.5$ Hz, 2H).

Similarly prepared from 6-chloro-2,9-dimethoxyacridine was β -alanine, N-(6-chloro-2-methoxyacridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester dihydrochloride,

Compound XIII. ^1H NMR of the free base: δ 7.96-8.17 (m, 3H), 7.29-7.52 (m, 3H), 4.19 (t, $J = 5.8$ Hz, 2H), 4.00 (s, 3H), 3.89 (t, $J = 5.1$ Hz, 2H), 3.47 (t, $J = 6.8$ Hz, 4H), 2.91 (t, $J = 6.8$ Hz, 4H), 2.83 (t, $J = 5.8$ Hz, 2H), 2.67 (t, $J = 5.5$ Hz, 2H).

Example 5

β -alanine, [N,N-bis(2-chloroethyl)], 3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl ester dihydrochloride, Compound XI.

Step A β -Alanine, [N, N-bis(2-triisopropylsilyloxy)ethyl]ethyl ester

A slurry of β -alanine ethyl ester hydrochloride (1.99 g, 12.9 mmol), K_2CO_3 (6.0g, 43.4 mmol) and iodoethyl triisopropylsilyl ether (9.47 g, 28.9 mmol) in acetonitrile (175 mL) were refluxed for 5-7 days. After vacuum evaporation of the solvent, the solid was triturated with CH_2Cl_2 . The organic layer was washed with dilute $\text{Na}_2\text{CO}_3(\text{aq})$, then with brine and dried over anhydrous Na_2SO_4 . The crude product was purified by silica gel chromatography (1:4 EtOAc / hexane) to provide 5.60 g of the oil, β -alanine, [N, N-bis(2-triisopropylsilyloxy)ethyl]ethyl ester, (83.1%). ^1H NMR: δ 4.12 (q, $J = 7.1$ Hz, 2H), 3.73 (t, $J = 6.8$ Hz, 4H), 2.92 (t, $J = 7.3$ Hz, 2H), 2.70 (t, $J = 6.6$ Hz, 4H), 2.46 (t, $J = 7.4$ Hz, 2H), 1.4 - 0.9 (m, 45H, includes triplet at 1.25 (3H) and singlets at 1.06 and 1.05).

Step B β -Alanine, N, N-bis(2-triisopropylsilyloxy)ethyl

The β -alanine, [N, N-bis(2-triisopropylsilyloxy)-ethyl]ethyl ester from Step A above (5.60 g, 10.8 mmol) and lithium hydroxide (0.59 g, 14.1 mmol) were stirred in

ethanol and refluxed for 3h. The solvent was removed and the crude product was partitioned between CH_2Cl_2 and dilute $\text{NaHCO}_3(\text{aq})$. The organic layer was washed with brine, dried over anhydrous Na_2SO_4 , and stripped to give β -alanine, N, N-bis(2-triisopropylsilyloxy)ethyl as a pale yellow oil (5.03 g, 95.1% yield). ^1H NMR: δ 3.90 (t, J = 5.5 Hz, 4H), 3.04 (t, J = 6.2 Hz, 2H), 2.92 (t, J = 5.5 Hz, 4H), 2.50 (t, J = 6.1 Hz, 2H), 1.06 (s, 42H).

Step C β -Alanine, [N,N-bis(2-hydroxyethyl)], 3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl ester

The β -alanine, N, N-bis(2-triisopropylsilyloxy)ethyl from Step B above (51.0 mg, 0.104 mmol) was stirred under N_2 in CH_2Cl_2 (1 mL). While chilling on an ice bath, SOCl_2 (0.5 mL) was added dropwise and the reaction was stirred for 2.25 h. After stripping the reaction mixture to remove excess SOCl_2 , dry CH_2Cl_2 (0.5 mL) was added and the solution was chilled in an ice bath while under N_2 . A chilled slurry of 9-(3-hydroxy)propylamino-6-chloro-2-methoxy-acridine (29.0 mg, 91.5 mmol) in CH_2Cl_2 (1 mL) was added. After 0.5 h the mixture was partitioned between CH_2Cl_2 and aqueous NaHCO_3 . The organic layer was washed with brine, dried with anhydrous Na_2SO_4 , and stripped. The gum obtained was triturated with hexane and the hexane extract was stripped to obtain a very crude mixture (53.5 mg) of triisopropylsilyl protected starting material and product.

To remove the triisopropylsilyl groups, a portion of the crude protected diol (33.1 mg) was stirred in ice cold THF (1 mL). After the addition of HF/pyridine (0.5 mL) the mixture was stirred at ambient temperature under a N_2 filled balloon for 2.5 h. The reaction mix was partitioned between CH_2Cl_2 and $\text{NaHCO}_3(\text{aq})$ and the organic layer was washed several times with dilute $\text{NaHCO}_3(\text{aq})$ to remove excess HF/pyridine. After preliminary drying with brine, then with anhydrous Na_2SO_4 , the solvent was stripped off to give crude diol (13.1 mg).

This was combined with additional crude diol (5.0 mg) and purified by C-18 preparative TLC with 95 CH₂Cl₂ / 5 iPA / 1 TFA as eluent to obtain the diol TFA salt. After partitioning the salt between CH₂Cl₂ and NaHCO₃(aq), the organic layer was dried with brine, then with anhydrous Na₂SO₄, and stripped to give the free base of the diol, β-alanine, [N,N-bis(2-hydroxyethyl)], 3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl ester, (5.0 mg). ¹H NMR: δ 7.92-8.25 (m, 3H), 7.23-7.47 (m, 3H), 4.30 (t, J = 5.7 Hz, 2H), 3.98 (s, 3H), 3.81 (t, J = 6.2 Hz, 2H), 3.64 (t, J = 4.9 Hz, 4H), 2.86 (t, J = 6.1 Hz, 2H), 2.67 (t, J = 4.9 Hz, 4H), 2.51 (t, J = 5.9 Hz, 2H), 2.04 (apparent quintet, 2H).

Step D β-Alanine, [N,N-bis(2-chloroethyl)], 3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl ester dihydrochloride, Compound XI.

The β-alanine, [N,N-bis(2-hydroxyethyl)], 3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl ester from above (4.0 mg, 0.0073 mmol) was dissolved in CH₂Cl₂ (1 mL) and chilled in an ice/water bath. Ice cold SOCl₂ (0.1 mL) was added and the reaction was allowed to stir for 4 h at room temperature. The reaction mixture was stripped to remove solvent, triturated with hexane, and partitioned between CH₂Cl₂ and NaHCO₃(aq). After the organic layer was dried with brine, then with anhydrous Na₂SO₄ and stripped, the dichloro- compound was obtained as a yellow gum. ¹H NMR: δ 7.8-8.2 (m, 3H), 7.2-7.5 (m, 3H), 4.35 (t, J = 5.9 Hz, 2H), 3.85-4.10 (3.99, s, OMe and 3.9-4.0, m, NHCH₂, total 5H), 3.48 (t, J = 6.9 Hz, 4H), 2.9-3.0 (m, 6H), 2.49 (t, J = 6.6 Hz, 2H), 2.1-2.3 (m, 2H).

The free amine was stirred in chilled CH₂Cl₂, acidified with 1M HCl in ether and stripped with a few drops of methanol to obtain the desired compound, β-alanine, [N,N-bis(2-chloroethyl)], 3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl ester dihydrochloride (2.5 mg), (3.5 mg, 81 %), as a yellow solid.

In the same manner as given in the foregoing Step C, but using 6-chloro-9-(2-hydroxy)ethylamino-2-methoxy-acridine instead of 6-chloro-9-(3-hydroxy)propylamino-

2-methoxy-acridine, was prepared the analogous diol. ^1H NMR: δ 7.96-8.13 (m, 3H), 7.20-7.47 (m, 3H), 4.76 (t, $J = 4.9$ Hz, 2H), 3.99 (s, 3H), 3.92-4.14 (m, 2H), 3.60 (t, $J = 5.1$ Hz, 4H), 2.78 (t, $J = 6.1$ Hz, 2H), 2.63 (t, $J = 5.1$ Hz, 4H), 2.45 (t, $J = 6.0$ Hz, 2H). By analogy to Step D this was converted to β -alanine, [N,N-bis(2-chloroethyl)], 2-[(6-chloro-2-methoxyacridin-9-yl)amino]ethyl ester dihydrochloride, Compound XII. ^1H NMR: δ 7.94-8.20 (m), 7.20-7.50 (m), 4.42 ($\text{CH}_2\text{OC}=\text{O}$), 3.90-4.10 (OCH_3 , NHCH_2), 3.46 (CH_2Cl), 2.82 ($\text{N}(\text{CH}_2)_3$), 2.39-2.56 ($\text{CH}_2\text{C}=\text{O}$).

Example 6

[N,N-Bis(2-chloroethyl)]-2-aminoethyl 4,5',8-trimethyl-4'-psoralenacetate hydrochloride, Compound XIV

Step A: [N,N-Bis(2-hydroxyethyl)]-2-aminoethyl 4,5',8-trimethyl-4'-psoralenacetate

A slurry of methyl 4,5',8-trimethyl-4'-psoralenacetate (250 mg, 0.832 mmol), triethanolamine (12 mL) and 1M HCl in ether (2 mL) were stirred at 100°C for 2 h. The resulting clear brown solution was allowed to cool to room temperature and partitioned between CH_2Cl_2 and saturated $\text{NaHCO}_3(\text{aq})$. The organic layer was rinsed several times with saturated $\text{NaHCO}_3(\text{aq})$. After drying with anhydrous Na_2SO_4 , solvent was removed *in vacuo* and the residue was partitioned between CH_2Cl_2 and 1M aq. HCl. The aqueous layer was rinsed several times with CH_2Cl_2 and then made basic with $\text{K}_2\text{CO}_3(\text{s})$ in the presence of the organic solvent. The organic layer containing the neutral product was rinsed with water several times, then dried and concentrated. A repetition of the acid-base extraction procedure gave the desired product as a beige solid (84.3 mg, 24.3%): ^1H NMR: δ 7.53 (s, 1H), 6.24 (s, 1H), 4.23 (t, $J = 5.4$ Hz, 2H), 3.69 (s, 2H), 3.56 (t, $J = 5.3$ Hz, 4H), 2.82 (t, $J = 5.4$ Hz, 2H), 2.69 (t, $J = 5.3$ Hz, 4H), 2.57 (s, 3H), 2.51 (d, $J = 1.1$ Hz, 3H), 2.47 (s, 3H).

Step B: [N,N-Bis(2-chloroethyl)]-2-aminoethyl 4,5',8-trimethyl-4'-psoralenacetate hydrochloride

Thionyl chloride (0.2 mL) was added to an ice cold mixture of the above diol (9.8 mg, 0.023 mmol) in CH_2Cl_2 (1 mL) and stirred at room temperature overnight under nitrogen. The resulting slurry was concentrated then triturated with hexane to give the desired product (6.2 mg, 53.9%) as an off-white solid: ^1H NMR (CD_3OD): δ 7.71 (s, 1H), 6.28 (s, 1H), 4.56 (t, $J = 4.8$ Hz, 2H), 3.95 (t, $J = 6.1$ Hz, 4H), 3.89 (s, 2H), 3.60-3.83 (m, 6H), 2.54 (s, 3H), 2.53 (s, 3H), 2.50 (s, 3H).

Example 7

Synthesis of β -alanine, N-(acridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl amide (Compound XV)

Step A 2-[N',N'-Bis(2-hydroxyethyl)]-N-(*tert*-butoxycarbonyl)ethylenediamine

To a solution of N-(*tert*-butoxycarbonyl)ethanolamine (1.21 g, 7.5 mmol) and triethylamine (1.57 mL, 1.1 g, 11 mmol) in dry CH_2Cl_2 (25 mL) at 0°C was added methanesulfonyl chloride (0.64 mL, 0.95 g, 8.3 mmol) dropwise. The reaction was stirred at 0°C for 1 h, allowed to warm to 23°C and was stirred overnight. The volatiles were removed *in vacuo* to give the mesylate as a white solid. Diethanolamine (7.2 mL, 7.9 g, 75 mmol) was added and the reaction mixture was heated to 75°C with stirring for 6 h. The crude reaction mixture was partitioned between H_2O (60 mL) and CHCl_3 (4 x 20 mL). The combined organic layers were washed with brine (20 mL) and dried over Na_2SO_4 . Removal of solvent *in vacuo* gave 1.21 g (65%) of the diol as a thick- yellow oil, ^1H NMR: δ 5.51-5.39 (m, 1H), 3.61 (t, $J = 4.9$ Hz, 4H), 3.29-3.13 (m, 2H), 2.68-2.52 (m, 6H), 1-44 (s, 9H). The hydroxyl protons were not observed,

Step B 2-[N',N'-Bis(2-*tert*-butyldimethylsilyloxyethyl)]-N-(*tert*-butoxycarbonyl)ethylenediamine

To a stirred solution of the diol from step A (1.21 g, 4.87 mmol) and pyridine (1.59 mL, 1.55 g, 19.6 mmol) in dry CH₂Cl₂ (12 mL) at 0°C was added
5 *tert*-butyldimethylsilyl chloride (2.21 g, 14.7 mmol). The reaction mixture was allowed to warm to 23°C and was stirred for 2 d. The reaction mixture was diluted with CH₂Cl₂ (80 mL) and washed with H₂O (3 x 25 mL) and then brine (3 x 25 mL). The organic layer was dried over Na₂SO₄. Removal of solvent *in vacuo* gave 2.26 g (97%) of a pale yellow oil. ¹H NMR: δ 5.37-5.22 (m, 1H),
10 3.62 (t, J = 6.2 Hz, 4H), 3.19-3.08 (m, 2H) 2.63 (t, J = 6.2 Hz, 6H), 1.42 (s, 9H), 0.873 (s, 18H), 0.04 (s, 12H).

Step C 2-[N,N,Bis(2,*tert*-butyldimethylsilyloxyethyl)]ethylenediamine

To a flask containing the protected amine from step B (4.24 g, 8.89 mmol)
15 was added 5 mL of trifluoroacetic acid at 23°C. The reaction mixture was stirred for 15 minutes at 23°C followed by removal of the trifluoroacetic acid *in vacuo*. The crude product was partitioned between 2 N NaOH (100 mL) and CH₂Cl₂ (3 x 35 mL). The combined organic layers were dried over Na₂SO₄. Removal of solvent *in vacuo* gave 1.76 g (53%) of a yellow oil. ¹H NMR: δ 3.66 (t, J = 6.5
20 Hz, 4H), 2.72-2.53 (m, 8H), 1.72-1.63 (m, 2H), 0.87 (s, 18H), 0.02 (s, 12H).

Step D β-4Alanine, N-(*tert*-butoxycarbonyl), 2-[bis(2-*tert*-butyldimethylsilyloxyethyl)amino]ethyl amide

To a solution of 3-(N-*tert*-butoxycarbonyl)aminopropanoic acid (822.0
25 mg, 4.34 mmol) and 4-methylmorpholine (442.0 mg, 4.37 mmol) in 14 mL of dry THF at -15°C was added isobutylchloroformate (0.53 mL, 0.56 g, 4.1 mmol). The

reaction mixture was stirred at -15°C for 1 min followed by the addition of the amine from step C (1.72 g, 4.57 mmol). The reaction mixture was allowed to warm to 23°C and was stirred for 1 h. The mixture was then filtered, the precipitate was washed with THF (5 mL) and the filtrate was concentrated *in vacuo*. The remaining material was partitioned between 2 N NaOH (50 mL) and CH₂Cl₂ (3 x 20 mL). The combined organic layers were dried over Na₂SO₄ and the solvent removed *in vacuo* to give 2.25 g of a brownish yellow gum.

Purification of the crude material (2.25 g) by medium pressure liquid chromatography (silica gel, 1:1 CHCl₃/EtOAc) gave 627.0 mg (26%) of a pale yellow oil. ¹H NMR: δ 3.63 (t, J = 6.2 Hz, 4H), 3.54-3.35 (m, 4H), 3.20-3.19 (m, 2H), 2.71-2.50 (m, 6H), 1.43 (s, 9H), 0.89 (s, 18H), 0.05 (s, 12H). The amide and carbamate protons were not observed.

Step E β-Alanine, 2-(bis(2-*tert*-butyldimethylsilyloxyethyl)amino]ethyl amide

The protected amine formed in step D (627.0 mg, 1.14 mmol) was dissolved in trifluoroacetic acid (5 mL) at 23°C. The resulting solution was stirred for 5 min (until CO₂ evolution ceased) followed by removal of the trifluoroacetic acid *in vacuo*. The remaining material was partitioned between saturated NaHCO₃ (50 mL) and CH₂Cl₂ (3 x 20 mL). The combined organic layers were dried over Na₂SO₄ and the solvent removed *in vacuo* to give 203.4 mg (40%) of a pale yellow oil.

Step F β-Alanine, N-(acridin-9-yl), 2-[bis(2-*tert*-butyldimethylsilyloxyethyl)amino]ethyl amide

A mixture of the crude amine from step E (203.4 mg, 0.45 mmol), 9-methoxyacridine (96.8 mg, 0.46 mmol) and methanol (10 mL) was heated to

reflux for 4 h. The reaction mixture was allowed to cool to 23°C and was stirred for an additional 2.5 days. The methanol was removed *in vacuo* and the remaining material was partitioned between 2 N NaOH (50 mL) and CH₂Cl₂ (3 x 20 mL). The combined organic layers were dried over Na₂SO₄ and the solvent removed *in vacuo* to give 69.6 mg of a yellow oil. Purification of the crude material (69.6 mg) by TLC (silica gel, 1:1 CHCl₃/EtOAc) gave 23.4 mg (8.3 %) of a yellow oil. ¹H NMR: δ 8.19 (d, J = 8.8 Hz, 2H), 8.06 (d, J = 8.8 Hz, 2H), 7.65 (br t, J = 7.6 Hz, 2H), 7.36 (br t, J = 7-6 Hz, 2H), 6.8-6.7 (m, 1H), 4.06 (t, J = 5.6 Hz, 2H), 3.61 (t, J = 5.8 Hz, 4H), 3.37-3.32 (m, 2H), 2.72-2.61 (m, 6H), 2.51 (t, J = 5.5 Hz, 2H), 0.86 (s, 18H), 0.02 (s, 12H). The amine proton was not observed, ¹³C NMR: δ 172.1, 152.4, 149.3, 130.5, 129.3, 123.7, 118.0, 112.8, 62.3, 57.4, 54.1, 47.4, 38.2, 36.5, 26.4, 18.8, -4.8.

Step G β-Alanine, N-(acridin-9-yl), 2-[bis(2-hydroxyethyl)amino]ethyl amide dihydrochloride

To a stirred solution of the bis-protected diol from step F (22.0 mg, 0.04 mmol) in isopropanol (1.0 mL) was added a 5-6 N HCl/isopropanol solution (0.05 mL) at 23°C. The reaction mixture was stirred at 23°C for 17 h and the resultant yellow precipitate was collected by vacuum filtration. The yellow solid was rinsed with an additional 1.0 mL of isopropanol. Residual isopropanol was removed *in vacuo* (overnight) to give 11.4 mg (69%) of the diol dihydrochloride salt as a yellow solid. ¹H NMR (CD₃OD): δ 8.52 (d, J = 8.8 Hz, 2H), 7.96 (br t, J = 7.5 Hz, 2H), 7.82 (d, J = 8.4 Hz, 2H), 7.57 (br t, J = 7.5 Hz, 2H), 4.49 (t, J = 6.2 Hz, 2H), 3.91 (t, J = 4.8 Hz, 4H), 3.74-3.56 (m, 2H), 3.53-3.38 (m, 6H), 2.97 (t, J = 6.1 Hz, 2H). The amide, amine and hydroxyl protons were not observed.

Step H β -Alanine, N-(acridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl amide dihydrochloride


To a stirred suspension of the diol from step G (11.4 mg, 0.024 mmol) in CH_3CN (1.0 mL) was added SOCl_2 (0.12 mL, 200 mg, 1.7 mmol) at 23°C . The reaction mixture was stirred at 23°C for 15 minutes and the solution was heated to 50°C for 3.5 h. The resultant yellow precipitate was collected via vacuum filtration and was rinsed with CH_3CN (3 x 1.0 mL) and dried *in vacuo* to give 8.3 mg (67%) of a yellow powder (95% pure by HPLC). ^1H NMR (CD_3OD): δ 8.55 (d, $J = 8.7$ Hz, 2H), 8.00 (br t, $J = 7.7$ Hz, 2H), 7.84 (d, $J = 8.7$ Hz, 2H), 7.59 (br t, $J = 7.7$ Hz, 2H), 4.51 (t, $J = 6.2$ Hz, 2H), 3.98 (t, $J = 5.7$ Hz, 4H), 3.71 (t, $J = 5.7$ Hz, 4H), 3.65-3.55 (m, 2H), 3.55-3.42 (m, 2H), 2.99 (t, $J = 6.2$ Hz, 2H). The amide and amine protons were not observed.

Example 8

Hydrolysis of the Frangible Compounds

For the frangible compounds incorporating an ester group ("forward" and "reverse" esters) in the frangible linker, model compounds were studied to determine the amount of ester hydrolysis.

The reaction



where AcrNH indicates a 9-amino acridine bearing substituents as indicated in the following table, and n and R are as indicated, was studied. Table III shows the


rate enhancement for ester hydrolysis when the ester linkage is situated between, and in proximity to, an acridine ring and an alkylamino group. The hydrolysis rate is rapid regardless of whether the acridine moiety is positioned at the acid terminus of the ester, or at the alcohol terminus.

5

Table III

		Percent Hydrolysis at 100 minutes (aqueous solution, pH 8, 37 °C)		
Acridine Substituent(s)	n =	R = methyl	R = -(CH ₂) ₂ N(CH ₂ CH ₂ OH) ₂	R = -(CH ₂) ₃ N(CH ₂ CH ₂ OH) ₂
6-Cl, 2-OMe	1	28 %		
6-Cl, 2-OMe	2	22 %		
6-Cl, 2-OMe	3	5 %		
6-Cl, 2-OMe	4	2 %		
6-Cl, 2-OMe	7	<1 %		
2-CO ₂ CH ₃	2	9 %	55 %	57 %
2-CO ₂ CH ₃	3		18 %	
2-CO ₂ CH ₃	4		17 %	

10 For the reaction



15 where AcrNH indicates a 9-amino acridine bearing substituents as indicated in the following table, and n and R are as indicated, the following results were obtained:

Table IV

		Percent Hydrolysis at 100 minutes (aqueous solution, pH 8, 37 °C)		
Acridine Substituent(s)	n =	R = methyl	R = -(CH ₂) ₂ N(CH ₂ CH ₂ OH) ₂	R = -(CH ₂) ₃ N(CH ₂ CH ₂ OH) ₂
6-Cl, 2-OMe	2	2 %	99 %	
6-Cl, 2-OMe	3	2 %	65 %	

At pH 3, all compounds in Tables III and IV showed $\leq 1\%$ hydrolysis at 100 min.

The mustard compounds cannot be evaluated in the same manner since multiple degradation pathways occur simultaneously. Nevertheless, when Compound VIII is incubated under the same conditions as in Tables III and IV, the acridine acid is the major product ($\geq 95\%$) after long incubation times and 40% is formed at 100 minutes. This compares favorably to the table entry for the analogous diol (57% hydrolysis at 100 minutes).

It will be appreciated from the data in Tables III and IV that the hydrolysis rate of the ester linkage varies inversely with the length of the linker arm between the 9-aminoacridine moiety and the ester group (in Tables III and IV, as n increases, the amount of hydrolysis at 100 minutes decreases). This provides a method of tuning the hydrolysis rate of the compounds. This ability to tune the breakdown of the linker allows compound reactivity to be adjusted for various applications, as desired.

MATERIALS

The following materials were used in the following Examples:

While it is commercially available from Baxter Healthcare Corp., Deerfield, IL, Adsol used in this and the following experiments was made by sterile filtering the following mixture: 22 g glucose, 9 g NaCl, 7.5 g mannitol, and 0.27 g adenine in 1 liter of distilled water.

Quinacrine mustard was obtained from Aldrich Chemical Co., St. Louis, MO.

Whole blood was obtained from the Sacramento Blood Center (Sacramento CA).

5

Example 9

Inactivation of Vesicular Stomatitis Virus (VSV)

10 Stock solutions (typically 10–30 mM) of each compound are prepared by dissolving an appropriate amount of material in blood bank saline previously acidified with 2 mM H_3PO_4 , then quickly frozen in 1 mL aliquots. At the time of use, aliquots are warmed to $\leq 10^\circ\text{C}$ and used within one hour.

15 For preparation of packed red blood cells (PRBC), whole blood, with measured Hct, is centrifuged at 3800 rpm for 6 min. Supernatant plasma is removed and measured. Adsol is added to provide PRBC with 60% Hct. Plasma concentration is 15–20%.

20 A VSV (stock solution, approx. 10^9 pfu/mL, obtained from ATCC American Type Cell Culture, Rockville, MD) is diluted 1:10 into tissue culture medium (DMEM with 10% NCS) or into PBRC to provide the test medium which is aliquoted (1 mL) into 2 mL sterile o-ring tubes.

25 To each tube is added sufficient test compound solution to provide a test compound concentration of 10–300 μM . Each sample is quickly mixed by fully pipetting the mixture several times. Suspensions are incubated at ambient temperature for 4 h. Virus titer was ascertained following incubation of the treated medium in BHK (baby hamster kidney) host cells. PRBC was used directly rather than the supernatant alone. Virus kill was inversely proportional to the appearance of plaques in the cell cultures. The difference between the titer of the untreated test medium and that of a treated sample provides the log kill for the
30 compound at that concentration. The detection limit is $10^{1.4}$ pfu/mL.

In tissue culture medium, quinacrine mustard (QM), and Compounds IV, VI, XI, VII, and VIII inactivated >3 logs of VSV at <50 μ M test compound. Compound XII inactivated 2 logs at approx. 200 μ M. This compound is believed to be particularly unstable with respect to ester hydrolysis. As indicated in the first entry in Example 8, Table IV, the corresponding diol compound (β -alanine, [N,N-bis(2-hydroxyethyl)], 2-[(6-chloro-2-methoxyacridin-9-yl)amino]ethyl ester) was 99% hydrolyzed after 100 minutes at pH 8, 37 °C. It is likely that the mustard compound also underwent rapid hydrolysis. This illustrates the importance of the anchor moiety for directing the effector portion of the molecule to nucleic acid, and the importance of tuning the reactivity of the 9-aminoacridine class of compounds so that they are effective under conditions of actual use. Under the described inactivation protocol, hydrolysis of Compound XII is expected to be competitive with inactivation.

In PRBC, QM and Compounds IV, VI, VIII, V, and XIII inactivated >2 logs of VSV at <150 μ M of test compound.

Example 10

Inactivation of Yersinia enterocolitica

PRBC and stock solutions were prepared as for VSV in Example 9.

Yersinia (California Department of Health Services, Microbial Disease Laboratory, Berkeley, CA) is cultured in LB-broth at 37°C overnight on a shaker. A portion (10 mL) is centrifuged at 2500 rpm for 10 min in a 15 mL conical tube. The pellet is resuspended in 1 mL of Adsol to provide approx. 10^9 bacteria/mL. To measure the titer, the optical density is measured of a 1:100 dilution in Adsol ($OD_{610} = 0.2$ at 10^8 bacterial/mL). The bacterial stock is then diluted 1:100 into saline or PRBC to provide the test medium which is aliquoted (1 mL) into 2 mL o-ring sterile tubes.

To each tube is added a sufficient amount of the test compound solution to provide a test compound concentration of 10–300 μM . Each sample is quickly mixed by fully pipetting the mixture several times. It is then incubated for two hours at ambient temperature, then plated out on LB-agar starting with 100 μL sample starting at 10^{-1} dilution and continuing dilutions to 10^{-8} . The plates are incubated overnight at 37°C and the colonies are counted. The difference between the titer of the untreated test medium and that of a treated sample provides the log kill for the compound at that concentration. The detection limit is 10 bacteria/mL.

In saline, quinacrine mustard (QM) and Compounds IV, VI, VIII, V, IX, and X inactivated >2 logs of *Yersinia* at concentrations $\leq 200 \mu\text{M}$.

In PRBC, QM and Compounds VI, VIII, V, X, and XIII inactivated >2 logs of *Yersinia* at concentrations $\leq 200 \mu\text{M}$.

Example 11

Blood Function Assay After Introduction of a Compound of the Invention

One of the contemplated uses of the compounds of the invention involves the introduction of one or more of the compounds of the invention into blood or blood products intended for transfusion. The blood or blood product must remain suitable for transfusion after treatment with the compounds. To evaluate the effect of the compounds on red blood cell function, the compounds were tested as described below.

Packed red blood cells with a 50% hematocrit (Hct) is prepared by spinning whole blood with a known Hct at 2500 rpm for 6 min. The supernate is removed and measured. The suspension is diluted with a sufficient volume of Adsol to achieve the desired Hct.

1.5 mL of PRBC is placed in each 2 ml o-ring tube and enough of the stock solution of the test compound is added to achieve the desired concentration.

The samples are incubated at ambient temperature for 4 hours, then stored

overnight at 4°C. Hemolysis was determined as described in Hogman et al., Transfusion, 31:26-29 (1991).

A lysis standard is prepared for each sample by diluting 10 µM of the incubated mixture in two steps with water to give a final 1:4000 dilution.

5 For the assay, samples were removed from 4°C storage and warmed for <15 minutes. After vortexing briefly to mix, an aliquot was removed and spun for 2 minutes at 14,000 rpm. The supernate was removed and spun for 10 minutes at 14,000 rpm. The supernate was removed and diluted as needed in water. The absorbance at 414 nm of the lysis standards and the diluted supernates were read
10 against a water blank. Percent hemolysis was calculated as:

$$(100\% - 50\% \text{Hct}) \times (A_{414} \text{ of sample} \times \text{dilution factor}) / (A_{414} \text{ of lysis standard} \times 4000)$$

The A_{414} of the samples is uncorrected for any absorbance due to the presence of the compound of the invention. The results are given in Table Va.

Table Va
Hemolysis Data at Day 1

Compound and Concentration	Percent Hemolysis	Number of Samples Tested
BBS*	0.066	14
ABBS**	0.065	8
150 μ M QM***	0.220	14
300 μ M QM	0.320	14
150 μ M IV	0.091	14
300 μ M IV	0.109	14
150 μ M VI	0.103	14
300 μ M VI	0.140	14
150 μ M VIII	0.110	6
300 μ M VIII	0.135	6
150 μ M V	0.136	2
300 μ M V	0.149	2
150 μ M IX	0.116	2
300 μ M IX	0.099	2
150 μ M X	0.121	2
300 μ M X	0.153	2

*BBS = blood bank saline

**ABBS = acidic blood bank saline

***QM= quinacrine mustard

Extracellular potassium was measured using a Ciba Corning Model 614 K^+/Na^+ Analyzer (Ciba Corning Diagnostics Corp., Medford, MA). ATP was measured using Sigma procedures No. 366 (Sigma, St. Louis, MO).

Table Vb. shows the relative values of extracellular potassium relative to the control values of the untreated PRBC samples for that experiment. For example, a relative value of 1.03 meant that the treated sample has 3% more extracellular potassium concentration than the untreated control.

5

Table Vb. Relative Extracellular Potassium Levels (replicates)*

Compound	Concentration (μ M)	Day 1	Day 7	Day 14
IV	100	1.01 (1)	0.98 (1)	1.03 (1)
	200	1.05 (1)	1.15 (1)	1.01 (1)
	300	1.03 (1)	1.15 (1)	1.15 (1)
V	300	1.04 - 1.46 (4)	0.96 - 1.01 (4)	0.95 - 1.01 (4)

*[K+] (treated) / [K+] (untreated)

10

Table Vc. shows the relative values ATP relative to the control values of the untreated PRBC samples for that experiment. For example, a relative value of 1.03 meant that the treated sample has 3% more ATP than the untreated control.

Table Vc. Relative ATP Levels (replicates)*

Compound	Concentration (μ M)	Day 1	Day 7	Day 14
IV	100	1.01 (1)	0.93 (1)	0.94 (1)
	200	1.05 (1)	0.94 (1)	0.94 (1)
	300	1.03 (1)	0.93 (1)	0.92 (1)
V	300	0.96 - 1.00 (4)	0.91 - 1.01 (4)	0.94 - 1.01 (4)

15

*[ATP] (treated) / [ATP] (untreated)

Example 12

Inactivation of HIV by Compounds of the Invention

5 Cell associated HIV in TC Medium (Popovic *et al.*, *Science*, 224:497
(1984): H9-IIIb cells are suspended in TC Medium to provide a suspension with a
titer of approximately $\geq 10^6$ pfu/mL. To 2 mL aliquots of the test medium in 15
mL conical tubes is added a sufficient amount of test compound solution to
achieve the desired concentration of active material. The suspensions are
10 immediately mixed by fully pipetting several times, then vortexing briefly. The
samples are incubated at ambient temperature for 2-4 h, then centrifuged. The
pellets are resuspended in 1 mL of plaque assay diluent, then quickly frozen at -80
°C and titrated by a microplaque assay. (Hanson et al., *J. Clin. Micro.*, 28:2030
(1990)).

15 Compounds quinacrine mustard, IV and VI inactivated >3 logs of HIV at
 $\leq 25 \mu\text{M}$ of test compound.

Cell-associated HIV in PRBC: For assays run in PRBC, the packed cells
are prepared as described in the VSV assay. The HIV9-IIIb cells are added to the
20 Adsol prior to dilution of the centrifuged cells. The resultant suspension is mixed
by fully pipetting all the material. Upon completion of incubation of the test
compound, the samples are diluted with 3 mL of a 1:1 plasma:DMEM solution
containing 5 μL of heparin. The infected cells are then isolated using a ficol-
hypaque gradient, resuspended in 1 mL of the diluent, and frozen for later
25 titration.

Compounds quinacrine mustard, VI and V inactivated >3 logs of HIV at \leq
200 μM of test compound.

Cell-free HIV in PRBC: The protocol is similar to that described above,
30 except that cell-free HIV is added directly to the PRBC after preparation. After

incubation, the medium is centrifuged and the supernate is frozen for later titration.

Compounds quinacrine mustard, IV, V and VI inactivated >3 logs of HIV at $\leq 100 \mu\text{M}$ of test compound.

5

Although the forgoing invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent to those skilled in the art that certain changes and modifications may be practical. Therefore, the description and examples should not be construed as
10 limiting the scope of the invention, which is delineated by the appended claims. The entirety of United States Patent Numbers 5,559,250 and 5,399,719 are hereby incorporated by reference. All other patents and references cited herein are hereby incorporated by-reference.

5/7/98/100

CLAIMS

What is claimed is:

1. A compound for inactivating pathogens in a material, comprising:
5 a nucleic acid binding moiety;
an effector moiety, capable of forming a covalent bond with nucleic acid;
and a frangible linker covalently linking the nucleic acid moiety and the
effector moiety;

10 wherein the frangible linker degrades so as to no longer covalently link the
nucleic acid binding moiety and the effector moiety, under conditions which do
not render the material unsuitable for its intended purpose.


2. A compound according to claim 1, wherein the nucleic acid
15 binding moiety is selected from the group consisting of acridine, acridine
derivatives, psoralen, isopsoralen, and psoralen derivatives.

3. A compound according to claim 1, wherein the frangible linker
comprises a functional unit selected from the group consisting of forward esters,
reverse esters, forward amides, reverse amides, forward thioesters, reverse
20 thioesters, forward and reverse thionoesters, forward and reverse dithioic acids,
sulfates, forward and reverse sulfonates, phosphates, and forward and reverse
phosphonate groups.

4. A compound according to claim 1, wherein the effector group
25 comprises a functional unit which is an alkylating agent.

5. A compound according to claim 1, wherein the effector group
comprises a functional unit selected from the group consisting of mustard groups,
mustard group equivalents, epoxides, aldehydes, and formaldehyde synthons.

6. A compound having the formula:



where R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , and R_8 are independently selected from the group consisting of -H, $-R_{10}$, $-O-R_{10}$, $-NO_2$, $-NH_2$, $-NH-R_{10}$, $-N(R_{10})_2$, -F, -Cl, -Br, -I, $-C(=O)-R_{10}$, $-C(=O)-O-R_{10}$, and $-O-C(=O)-R_{10}$,

where $-R_{10}$ is independently H, $-C_{1-8}$ alkyl, $-C_{1-8}$ heteroalkyl, -aryl, -heteroaryl, $-C_{1-3}$ alkyl-aryl, $-C_{1-3}$ heteroalkyl-aryl, $-C_{1-3}$ alkyl-heteroaryl, $-C_{1-3}$ heteroalkyl-heteroaryl, -aryl- $-C_{1-3}$ alkyl, -aryl- $-C_{1-3}$ heteroalkyl, -heteroaryl- $-C_{1-3}$ alkyl, -heteroaryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ heteroalkyl, or $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ heteroalkyl;

R_{20} is -H or $-CH_3$; and


R_{21} is $-R_{11}-W-X-E$,

where $-R_{11}-$ is independently $-C_{1-8}$ alkyl-, $-C_{1-8}$ heteroalkyl-, -aryl-, -heteroaryl-, $-C_{1-3}$ alkyl-aryl-, $-C_{1-3}$ heteroalkyl-aryl-, $-C_{1-3}$ alkyl-heteroaryl-, $-C_{1-3}$ heteroalkyl-heteroaryl-, -aryl- $-C_{1-3}$ alkyl-, -aryl- $-C_{1-3}$ heteroalkyl-, -heteroaryl- $-C_{1-3}$ alkyl-, -heteroaryl- $-C_{1-3}$ heteroalkyl-, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ heteroalkyl-, $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ heteroalkyl-, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ heteroalkyl-, or $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ heteroalkyl-;

W is independently -C(=O)-O-, -O-C(=O)-, -C(=S)-O-, -O-C(=S)-, -C(=S)-S-, -S-C(=S)-, -C(=O)-S-, -S-C(=O)-, -O-S(=O)₂-O-, -S(=O)₂-O-, -O-S(=O)₂-, -C(=O)-NR₁₀-, -NR₁₀-C(=O)-, -O-P(=O)(-OR₁₀)-O-, -P(=O)(-OR₁₀)-O-, -O-P(=O)(-OR₁₀)-;

5 X is independently -R₁₁-; and

E is independently selected from the group consisting of -N(R₁₂)₂, -N(R₁₂)(R₁₃), -S-R₁₂, and




10 where -R₁₂ is -CH₂CH₂-G, where each G is independently -Cl, -Br, -I, -O-S(=O)₂-CH₃, -O-S(=O)₂-CH₂-C₆H₅, or -O-S(=O)₂-C₆H₄-CH₃;

and where R₁₃ is independently -C₁₋₈ alkyl, -C₁₋₈ heteroalkyl, -aryl, -heteroaryl, -C₁₋₃alkyl-aryl, -C₁₋₃heteroalkyl-aryl, -C₁₋₃alkyl-heteroaryl, -C₁₋₃heteroalkyl-heteroaryl, -aryl-C₁₋₃alkyl, -aryl-C₁₋₃heteroalkyl, -heteroaryl-C₁₋₃alkyl, -heteroaryl-C₁₋₃heteroalkyl, -C₁₋₃alkyl-aryl-C₁₋₃ alkyl, -C₁₋₃heteroalkyl-aryl-C₁₋₃ alkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃alkyl-aryl-C₁₋₃ heteroalkyl, -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃heteroalkyl-aryl-C₁₋₃ heteroalkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ heteroalkyl, or -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ heteroalkyl;

20 and all salts and stereoisomers (including enantiomers and diastereomers) thereof.

7. A compound having the formula:



wherein at least one of R_{44} , R_{55} , R_3 , R_4 , R_5 , and R_8 is -V-W-X-E, and the remainder of R_{44} , R_{55} , R_3 , R_4 , R_5 , and R_8 are independently selected from the group consisting of -H, $-R_{10}$, $-O-R_{10}$, $-NO_2$, $-NH_2$, $-NH-R_{10}$, $-N(R_{10})_2$, -F, -Cl, -Br, -I, $-C(=O)-R_{10}$, $-C(=O)-O-R_{10}$, and $-O-C(=O)-R_{10}$,

where $-R_{10}$ is independently H, $-C_{1-8}$ alkyl, $-C_{1-8}$ heteroalkyl, -aryl, -heteroaryl, $-C_{1-3}$ alkyl-aryl, $-C_{1-3}$ heteroalkyl-aryl, $-C_{1-3}$ alkyl-heteroaryl, $-C_{1-3}$ heteroalkyl-heteroaryl, -aryl- $-C_{1-3}$ alkyl, -aryl- $-C_{1-3}$ heteroalkyl, -heteroaryl- $-C_{1-3}$ alkyl, -heteroaryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ alkyl, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ heteroalkyl, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ heteroalkyl, or $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ heteroalkyl;

V is independently $-R_{11}-$, $-NH-R_{11}-$ or $-N(CH_3)-R_{11}-$, where $-R_{11}-$ is independently $-C_{1-8}$ alkyl-, $-C_{1-8}$ heteroalkyl-, -aryl-, -heteroaryl-, $-C_{1-3}$ alkyl-aryl-, $-C_{1-3}$ heteroalkyl-aryl-, $-C_{1-3}$ alkyl-heteroaryl-, $-C_{1-3}$ heteroalkyl-heteroaryl-, -aryl- $-C_{1-3}$ alkyl-, -aryl- $-C_{1-3}$ heteroalkyl-, -heteroaryl- $-C_{1-3}$ alkyl-, -heteroaryl- $-C_{1-3}$ heteroalkyl-, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ alkyl-aryl- $-C_{1-3}$ heteroalkyl-, $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ alkyl-, $-C_{1-3}$ heteroalkyl-aryl- $-C_{1-3}$ heteroalkyl-, $-C_{1-3}$ alkyl-heteroaryl- $-C_{1-3}$ heteroalkyl-, or $-C_{1-3}$ heteroalkyl-heteroaryl- $-C_{1-3}$ heteroalkyl-;

W is independently $-C(=O)-O-$, $-O-C(=O)-$, $-C(=S)-O-$, $-O-C(=S)-$, $-C(=S)-S-$, $-S-C(=S)-$, $-C(=O)-S-$, $-S-C(=O)-$, $-O-S(=O)_2-O-$, $-S(=O)_2-O-$,


-O-S(=O)₂-, -C(=O)-NR₁₀-, -NR₁₀-C(=O)-, -O-P(=O)(-OR₁₀)-O-,
 -P(=O)(-OR₁₀)-O-, -O-P(=O)(-OR₁₀)-;

X is independently -R₁₁-; and

E is independently selected from the group consisting of -N(R₁₂)₂,

-N(R₁₂)(R₁₃), -S-R₁₂,

and



where -R₁₂ is -CH₂CH₂-G, where each G is independently -Cl, -Br, -I,

-O-S(=O)₂-CH₃, -O-S(=O)₂-CH₂-C₆H₅, or -O-S(=O)₂-C₆H₄-CH₃;

and where R₁₃ is independently -C₁₋₈ alkyl, -C₁₋₈ heteroalkyl, -aryl,

-heteroaryl, -C₁₋₃alkyl-aryl, -C₁₋₃heteroalkyl-aryl, -C₁₋₃alkyl-heteroaryl,

-C₁₋₃heteroalkyl-heteroaryl, -aryl-C₁₋₃alkyl, -aryl-C₁₋₃heteroalkyl,

-heteroaryl-C₁₋₃alkyl, -heteroaryl-C₁₋₃heteroalkyl, -C₁₋₃alkyl-aryl-C₁₋₃ alkyl,

-C₁₋₃heteroalkyl-aryl-C₁₋₃ alkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃alkyl-aryl-C₁₋₃


heteroalkyl, -C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ alkyl, -C₁₋₃heteroalkyl-aryl-C₁₋₃

heteroalkyl, -C₁₋₃alkyl-heteroaryl-C₁₋₃ heteroalkyl, or

-C₁₋₃heteroalkyl-heteroaryl-C₁₋₃ heteroalkyl;


and all salts and stereoisomers (including enantiomers and diastereomers) thereof.

8. A compound having the formula:



and all salts thereof.


9. A compound having the formula:



and all salts thereof.

5


10. A compound having the formula:



and all salts thereof.

10


11. A compound having the formula:



and all salts thereof.

15


12. A compound having the formula:



and all salts thereof.

5


13. A compound having the formula:



and all salts thereof.


10

14. A compound having the formula:



and all salts thereof. 15. A compound having the formula:

15



and all salts thereof.

5

16. A method for inactivating pathogens in a material, comprising:
adding a compound according to claim 1 to the material; and
incubating said material.

10

17. A method according to claim 16, wherein the compound is added
to the material to form a final solution having a concentration of the compound of
between 1 and 500 μM .

15

18. A method according to claim 16, wherein the material is a
biological material.

20

19. A method according to claim 18, wherein the biological material
comprises a composition selected from the group consisting of blood, blood
products, plasma, platelet preparations, red blood cells, packed red blood cells,
serum, sweat, cerebrospinal fluid, saliva, urine, feces, semen, milk, tissue samples,
homogenized tissue samples, cell culture medium, cell cultures, viral cultures, and
cultures incorporating material derived from a living organism.

25

20. A method according to claim 18, wherein the material comprises a
blood product.

30

21. A method according to claim 18, wherein the material comprises
red blood cells.


22. A method according to claim 16, wherein the method comprises adding the compound to the material in an effective amount to inactivate at least about 2 logs of a pathogen in the material.

5 23. A method according to claim 16, wherein the time of incubation is at least about 1 to 48 hours.

AMENDED CLAIMS

[received by the International Bureau on 10 June 1998 (10.06.98);
original claim 15 amended; remaining claims unchanged (1 page)]


14. A compound having the formula:



and all salts thereof.

5

15. A compound having the formula:



10

and all salts thereof.

16. A method for inactivating pathogens in a material, comprising:

adding a compound according to claim 1 to the material; and

incubating said material.

15

17. A method according to claim 16, wherein the compound is added to the material to form a final solution having a concentration of the compound of between 1 and 500 μM .

20

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/00532

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D219/10 C07D493/04 A61L2/18 C07F9/64 C07F9/6561
C07D405/12 //(C07D493/04,311:00,307:00)

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61L C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DE 44 44 045 A (BEHRINGWERKE AG) 13 June 1996 see the whole document ---	1-7, 16-23
Y	WO 94 20090 A (STERITECH INC) 15 September 1994 see claims ---	1-7, 16-23
Y	WO 96 14737 A (STERITECH INC) 23 May 1996 see claims ---	1-7, 16-23
Y	WO 96 39818 A (CERUS CORP) 19 December 1996 see claims -----	1-7, 16-23

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

20 April 1998

Date of mailing of the international search report

24/04/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Henry, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/US 98/00532

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 4444045 A	13-06-96	AU 4032395 A	20-06-96
		CA 2164766 A	11-06-96
		CN 1132249 A	02-10-96
		EP 0720851 A	10-07-96
		JP 8225455 A	03-09-96
WO 9420090 A	15-09-94	AU 6402494 A	26-09-94
		US 5556958 A	17-09-96
		US 5659050 A	19-08-97
		US 5582994 A	10-12-96
		US 5665762 A	09-09-97
WO 9614737 A	23-05-96	US 5691132 A	25-11-97
		AU 4151396 A	06-06-96
		EP 0804074 A	05-11-97
		US 5559250 A	24-09-96
WO 9639818 A	19-12-96	AU 6104996 A	30-12-96
		CA 2199731 A	19-12-96
		EP 0773716 A	21-05-97